https://trial.medpath.com/news/natco-pharma-invests-14-million-in-egenesis-deepening-its-bet-on-xenotransplantation 2026-08-25T14:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-invests-14-million-in-egenesis-deepening-its-bet-on-xenotransplantation 2026-08-25T14:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/allegheny-health-network-and-start-center-announce-strategic-collaboration-to-expand-early-phase-cancer-trial-access-in-western-pennsylvania 2026-08-25T13:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allegheny-health-network-and-start-center-announce-strategic-collaboration-to-expand-early-phase-cancer-trial-access-in-western-pennsylvania 2026-08-25T13:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-launches-orbitrap-isora-bringing-molecular-level-isotope-ratio-analysis-to-more-labs 2026-08-25T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-launches-orbitrap-isora-bringing-molecular-level-isotope-ratio-analysis-to-more-labs 2026-08-25T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-files-vamikibart-for-regulatory-approval-in-japan-for-uveitic-macular-edema 2026-08-25T11:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-files-vamikibart-for-regulatory-approval-in-japan-for-uveitic-macular-edema 2026-08-25T11:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/cambrex-high-point-completes-fda-pmda-and-tga-pre-approval-inspections-advancing-commercial-manufacturing-capabilities 2026-08-25T11:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambrex-high-point-completes-fda-pmda-and-tga-pre-approval-inspections-advancing-commercial-manufacturing-capabilities 2026-08-25T11:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/central-venous-catheter-use-remains-common-at-hemodialysis-initiation-despite-guideline-recommendations 2026-08-25T11:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/central-venous-catheter-use-remains-common-at-hemodialysis-initiation-despite-guideline-recommendations 2026-08-25T11:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/revier-therapeutics-launches-with-eur6m-seed-financing-to-pioneer-class-iia-hdac-inhibitors-for-cardiometabolic-disease 2026-08-25T11:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revier-therapeutics-launches-with-eur6m-seed-financing-to-pioneer-class-iia-hdac-inhibitors-for-cardiometabolic-disease 2026-08-25T11:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/cha-biotech-secures-government-backing-to-advance-cell-and-gene-therapy-platforms-toward-clinical-development 2026-08-25T10:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cha-biotech-secures-government-backing-to-advance-cell-and-gene-therapy-platforms-toward-clinical-development 2026-08-25T10:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/tulsa-pro-mri-guided-prostate-ablation-expands-to-sutter-health-and-ssm-health-as-incision-free-alternative-to-surgery 2026-08-25T09:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tulsa-pro-mri-guided-prostate-ablation-expands-to-sutter-health-and-ssm-health-as-incision-free-alternative-to-surgery 2026-08-25T09:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/abio-advances-lanfa-as-a-next-generation-alternative-to-peg-in-drug-delivery 2026-08-25T07:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abio-advances-lanfa-as-a-next-generation-alternative-to-peg-in-drug-delivery 2026-08-25T07:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-leqvio-label-to-recognize-ldl-c-reduction-lowers-cardiovascular-event-risk 2026-08-25T06:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-leqvio-label-to-recognize-ldl-c-reduction-lowers-cardiovascular-event-risk 2026-08-25T06:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-fda-approved-metabolic-drug-starves-cancer-cells-to-death-in-lab-study 2026-08-25T06:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repurposed-fda-approved-metabolic-drug-starves-cancer-cells-to-death-in-lab-study 2026-08-25T06:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-expands-emergency-import-program-to-14-unlicensed-essential-medicines 2026-08-25T05:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-expands-emergency-import-program-to-14-unlicensed-essential-medicines 2026-08-25T05:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/seoul-st-mary-s-hospital-team-selected-for-national-quantum-computing-project-targeting-cardiovascular-precision-medicine 2026-08-25T05:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seoul-st-mary-s-hospital-team-selected-for-national-quantum-computing-project-targeting-cardiovascular-precision-medicine 2026-08-25T05:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-japanese-approval-for-pegfilgrastim-biosimilar 2026-08-25T05:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-secures-japanese-approval-for-pegfilgrastim-biosimilar 2026-08-25T05:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/light-driven-method-builds-3d-molecular-scaffolds-to-expand-drug-discovery-options 2026-08-25T05:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-driven-method-builds-3d-molecular-scaffolds-to-expand-drug-discovery-options 2026-08-25T05:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/oura-s-ipo-filing-reveals-a-health-data-platform-not-just-a-wearables-company 2026-08-25T05:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oura-s-ipo-filing-reveals-a-health-data-platform-not-just-a-wearables-company 2026-08-25T05:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/sillajen-s-bal0891-wins-fda-orphan-drug-designation-for-acute-myeloid-leukemia 2026-08-25T04:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sillajen-s-bal0891-wins-fda-orphan-drug-designation-for-acute-myeloid-leukemia 2026-08-25T04:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-and-medical-college-of-wisconsin-report-breakthrough-point-of-care-saliva-cancer-screening-results 2026-08-25T00:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pattern-computer-and-medical-college-of-wisconsin-report-breakthrough-point-of-care-saliva-cancer-screening-results 2026-08-25T00:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-searches-100-million-possibilities-to-democratize-3d-printing-of-nasa-s-grcop-42-alloy 2026-08-25T00:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-searches-100-million-possibilities-to-democratize-3d-printing-of-nasa-s-grcop-42-alloy 2026-08-25T00:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-doses-first-patient-in-phase-3-study-of-asp2138-a-subcutaneous-bispecific-t-cell-engager-for-cldn18-2-positive-gastric-cancer 2026-08-25T00:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-doses-first-patient-in-phase-3-study-of-asp2138-a-subcutaneous-bispecific-t-cell-engager-for-cldn18-2-positive-gastric-cancer 2026-08-25T00:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-launches-300-mg-omlyclo-omalizumab-biosimilar-across-key-european-markets 2026-08-24T23:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-launches-300-mg-omlyclo-omalizumab-biosimilar-across-key-european-markets 2026-08-24T23:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-therapeutic-equivalence-evaluations-for-generic-drugs 2026-08-24T22:55:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-therapeutic-equivalence-evaluations-for-generic-drugs 2026-08-24T22:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/nad-precursor-supplements-may-undermine-pancreatic-cancer-chemotherapy-study-warns 2026-08-24T20:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nad-precursor-supplements-may-undermine-pancreatic-cancer-chemotherapy-study-warns 2026-08-24T20:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/four-gene-fatty-acid-metabolism-signature-distinguishes-diabetic-foot-ulcers-with-high-diagnostic-accuracy 2026-08-24T19:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-gene-fatty-acid-metabolism-signature-distinguishes-diabetic-foot-ulcers-with-high-diagnostic-accuracy 2026-08-24T19:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/image-guided-automation-cuts-organoid-culture-hands-on-time-by-22-hours-weekly 2026-08-24T19:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/image-guided-automation-cuts-organoid-culture-hands-on-time-by-22-hours-weekly 2026-08-24T19:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/government-of-canada-invests-in-workforce-training-to-support-life-sciences-and-biomanufacturing-sector 2026-08-24T19:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/government-of-canada-invests-in-workforce-training-to-support-life-sciences-and-biomanufacturing-sector 2026-08-24T19:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/twinstrand-and-university-of-washington-win-245-2-million-final-judgment-against-guardant-health-in-duplex-sequencing-patent-case 2026-08-24T18:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/twinstrand-and-university-of-washington-win-245-2-million-final-judgment-against-guardant-health-in-duplex-sequencing-patent-case 2026-08-24T18:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-adds-two-behavioral-health-firms-to-tempo-pilot-including-an-ai-voice-agent-for-talk-therapy 2026-08-24T17:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-adds-two-behavioral-health-firms-to-tempo-pilot-including-an-ai-voice-agent-for-talk-therapy 2026-08-24T17:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-achieves-first-ever-profit-before-tax-on-strong-tavr-growth 2026-08-24T17:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peijia-medical-achieves-first-ever-profit-before-tax-on-strong-tavr-growth 2026-08-24T17:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/a-six-year-chase-to-starve-a-deadly-mold-new-3-22m-grant-targets-aspergillus-food-supply 2026-08-24T17:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-six-year-chase-to-starve-a-deadly-mold-new-3-22m-grant-targets-aspergillus-food-supply 2026-08-24T17:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/precipio-vs-biodesix-diverging-strategies-in-specialty-cancer-diagnostics 2026-08-24T17:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precipio-vs-biodesix-diverging-strategies-in-specialty-cancer-diagnostics 2026-08-24T17:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/azenta-appoints-dr-martin-madaus-as-interim-ceo-amid-leadership-transition 2026-08-24T17:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azenta-appoints-dr-martin-madaus-as-interim-ceo-amid-leadership-transition 2026-08-24T17:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/agc-and-neusignal-therapeutics-collaborate-to-advance-ntx-083-an-oral-alzheimer-s-disease-candidate-toward-u-s-clinical-trials 2026-08-24T16:52:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-and-neusignal-therapeutics-collaborate-to-advance-ntx-083-an-oral-alzheimer-s-disease-candidate-toward-u-s-clinical-trials 2026-08-24T16:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-sephience-sepiapterin-data-reinforce-broad-pku-benefits-including-diet-liberalization-and-sustained-metabolic-control 2026-08-24T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-sephience-sepiapterin-data-reinforce-broad-pku-benefits-including-diet-liberalization-and-sustained-metabolic-control 2026-08-24T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-analysis-accelerates-clinical-development-in-biopharma 2026-08-24T16:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-analysis-accelerates-clinical-development-in-biopharma 2026-08-24T16:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/viva-foundation-to-spotlight-26-late-breaking-clinical-trials-at-the-veins-and-viva-2026 2026-08-24T16:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viva-foundation-to-spotlight-26-late-breaking-clinical-trials-at-the-veins-and-viva-2026 2026-08-24T16:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/cellares-to-lay-off-100-employees-after-losing-large-cell-therapy-manufacturing-partner 2026-08-24T16:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellares-to-lay-off-100-employees-after-losing-large-cell-therapy-manufacturing-partner 2026-08-24T16:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/urinalysis-market-projected-to-reach-7-16-billion-by-2031-driven-by-automation-and-point-of-care-adoption 2026-08-24T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urinalysis-market-projected-to-reach-7-16-billion-by-2031-driven-by-automation-and-point-of-care-adoption 2026-08-24T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/ashland-launches-permexatm-sodium-caprate-to-advance-oral-biologics-delivery 2026-08-24T14:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ashland-launches-permexatm-sodium-caprate-to-advance-oral-biologics-delivery 2026-08-24T14:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-brinsupri-brensocatib-as-first-in-class-treatment-for-non-cystic-fibrosis-bronchiectasis 2026-08-24T14:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-brinsupri-brensocatib-as-first-in-class-treatment-for-non-cystic-fibrosis-bronchiectasis 2026-08-24T14:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-engages-synex-as-cro-to-advance-ibc101-cd19xcd22-bivalent-car-t-therapy-in-south-korea 2026-08-24T14:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-engages-synex-as-cro-to-advance-ibc101-cd19xcd22-bivalent-car-t-therapy-in-south-korea 2026-08-24T14:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/amplifica-appoints-hans-hofland-ph-d-as-chief-development-officer-and-william-humphries-to-board-of-directors 2026-08-24T14:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplifica-appoints-hans-hofland-ph-d-as-chief-development-officer-and-william-humphries-to-board-of-directors 2026-08-24T14:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/cognitive-ai-as-a-teammate-cmu-researchers-chart-a-path-for-human-ai-collaboration-in-healthcare 2026-08-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognitive-ai-as-a-teammate-cmu-researchers-chart-a-path-for-human-ai-collaboration-in-healthcare 2026-08-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/citywide-rapid-whole-genome-sequencing-achieves-53-diagnostic-yield-in-critically-ill-children-reshaping-picu-standard-of-care 2026-08-24T12:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citywide-rapid-whole-genome-sequencing-achieves-53-diagnostic-yield-in-critically-ill-children-reshaping-picu-standard-of-care 2026-08-24T12:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-doses-first-patient-in-phase-1-2-function-dmd-trial-for-pbgene-dmd 2026-08-24T11:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-doses-first-patient-in-phase-1-2-function-dmd-trial-for-pbgene-dmd 2026-08-24T11:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/edx-medical-raises-ps2-7m-at-44-premium-to-expand-employee-health-screening-service 2026-08-24T09:51:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edx-medical-raises-ps2-7m-at-44-premium-to-expand-employee-health-screening-service 2026-08-24T09:51:48+00:00 hourly 0.9 https://trial.medpath.com/news/astri-and-saint-francis-university-sign-mou-to-advance-ai-enabled-biomaterials-and-digital-health-innovation 2026-08-24T09:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astri-and-saint-francis-university-sign-mou-to-advance-ai-enabled-biomaterials-and-digital-health-innovation 2026-08-24T09:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-sugar-molecule-points-to-new-vaccine-antibody-and-diagnostic-routes-for-drug-resistant-hospital-fungus 2026-08-24T08:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthetic-sugar-molecule-points-to-new-vaccine-antibody-and-diagnostic-routes-for-drug-resistant-hospital-fungus 2026-08-24T08:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/isofol-expands-arfolitixorin-phase-ib-ii-colorectal-cancer-trial-sites-to-accelerate-patient-recruitment 2026-08-24T07:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isofol-expands-arfolitixorin-phase-ib-ii-colorectal-cancer-trial-sites-to-accelerate-patient-recruitment 2026-08-24T07:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/counterfeit-and-diverted-cancer-drugs-bengaluru-probe-reaches-90-hospitals-as-delhi-police-bust-rs-9-crore-racket 2026-08-24T06:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/counterfeit-and-diverted-cancer-drugs-bengaluru-probe-reaches-90-hospitals-as-delhi-police-bust-rs-9-crore-racket 2026-08-24T06:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/screen-time-in-infancy-and-early-schooling-linked-to-poorer-academic-performance-and-working-memory 2026-08-24T06:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/screen-time-in-infancy-and-early-schooling-linked-to-poorer-academic-performance-and-working-memory 2026-08-24T06:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-real-food-show-budget-meal-claims-fail-independent-price-checks 2026-08-24T05:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-s-real-food-show-budget-meal-claims-fail-independent-price-checks 2026-08-24T05:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/illegal-imports-of-wegovy-and-mounjaro-surge-3-5-fold-in-korea-in-first-half-of-2026 2026-08-24T04:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illegal-imports-of-wegovy-and-mounjaro-surge-3-5-fold-in-korea-in-first-half-of-2026 2026-08-24T04:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-s-hunterase-wins-approval-in-india-and-taiwan-expanding-reach-in-asia-s-rare-disease-market 2026-08-24T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-s-hunterase-wins-approval-in-india-and-taiwan-expanding-reach-in-asia-s-rare-disease-market 2026-08-24T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/maharashtra-fda-chief-tukaram-mundhe-s-food-safety-crackdown-highlights-health-risks-of-repeated-cooking-oil-use 2026-08-24T03:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maharashtra-fda-chief-tukaram-mundhe-s-food-safety-crackdown-highlights-health-risks-of-repeated-cooking-oil-use 2026-08-24T03:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/pulnovo-medical-enrolls-first-u-s-patients-in-pulse-lhd-ide-trial-of-padn-for-pulmonary-hypertension-associated-with-left-heart-disease 2026-08-24T03:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulnovo-medical-enrolls-first-u-s-patients-in-pulse-lhd-ide-trial-of-padn-for-pulmonary-hypertension-associated-with-left-heart-disease 2026-08-24T03:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/rznomics-joins-lilly-gateway-labs-in-san-diego-to-accelerate-rna-editing-therapeutics 2026-08-24T03:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rznomics-joins-lilly-gateway-labs-in-san-diego-to-accelerate-rna-editing-therapeutics 2026-08-24T03:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/small-cap-biotech-and-pharma-weekly-wrap-highlights-sector-momentum 2026-08-24T02:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/small-cap-biotech-and-pharma-weekly-wrap-highlights-sector-momentum 2026-08-24T02:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-taihe-biotech-s-apixaban-oral-film-beqia-for-substantive-review-pdufa-date-set-for-april-22-2027 2026-08-24T02:58:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-taihe-biotech-s-apixaban-oral-film-beqia-for-substantive-review-pdufa-date-set-for-april-22-2027 2026-08-24T02:58:48+00:00 hourly 0.9 https://trial.medpath.com/news/jw-pharmaceutical-rebrands-frenz-into-a-total-eye-care-megabrand-spanning-drugs-cosmetics-devices-and-food 2026-08-24T02:57:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jw-pharmaceutical-rebrands-frenz-into-a-total-eye-care-megabrand-spanning-drugs-cosmetics-devices-and-food 2026-08-24T02:57:48+00:00 hourly 0.9 https://trial.medpath.com/news/equine-strangles-outbreak-prompts-fair-cancellations-and-precautionary-measures-in-northeast-wisconsin 2026-08-24T01:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/equine-strangles-outbreak-prompts-fair-cancellations-and-precautionary-measures-in-northeast-wisconsin 2026-08-24T01:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/anbogen-and-university-of-tokyo-partner-to-evaluate-abt-301-across-multiple-solid-tumors-via-comparative-oncology 2026-08-24T00:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anbogen-and-university-of-tokyo-partner-to-evaluate-abt-301-across-multiple-solid-tumors-via-comparative-oncology 2026-08-24T00:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/9-11-victim-identified-using-first-of-its-kind-genetic-genealogy-technique 2026-08-24T00:48:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/9-11-victim-identified-using-first-of-its-kind-genetic-genealogy-technique 2026-08-24T00:48:15+00:00 hourly 0.9 https://trial.medpath.com/news/dogs-and-humans-share-metabolic-biomarkers-of-mortality-dog-aging-project-study-finds 2026-08-24T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogs-and-humans-share-metabolic-biomarkers-of-mortality-dog-aging-project-study-finds 2026-08-24T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/novotech-strengthens-presence-in-japan-with-opening-of-tokyo-office 2026-08-23T23:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novotech-strengthens-presence-in-japan-with-opening-of-tokyo-office 2026-08-23T23:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/eight-year-old-louisiana-girl-dies-after-contracting-rare-brain-eating-amoeba-following-lake-swim 2026-08-23T23:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-year-old-louisiana-girl-dies-after-contracting-rare-brain-eating-amoeba-following-lake-swim 2026-08-23T23:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/nagoya-university-and-fujifilm-develop-next-generation-mrna-delivery-technology-with-circular-rna-and-novel-lipid-nanoparticles 2026-08-23T21:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nagoya-university-and-fujifilm-develop-next-generation-mrna-delivery-technology-with-circular-rna-and-novel-lipid-nanoparticles 2026-08-23T21:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-mrna-cancer-immunotherapy-shows-promise-in-high-risk-melanoma-former-fda-chief-says 2026-08-23T19:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-mrna-cancer-immunotherapy-shows-promise-in-high-risk-melanoma-former-fda-chief-says 2026-08-23T19:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/debut-novel-freight-explores-a-10-million-pharmaceutical-drug-heist-through-the-lens-of-the-trucking-industry 2026-08-23T17:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debut-novel-freight-explores-a-10-million-pharmaceutical-drug-heist-through-the-lens-of-the-trucking-industry 2026-08-23T17:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/dissolvable-3d-printed-microneedle-patch-aims-to-improve-localised-skin-cancer-treatment 2026-08-23T17:12:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dissolvable-3d-printed-microneedle-patch-aims-to-improve-localised-skin-cancer-treatment 2026-08-23T17:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/connecticut-officials-warn-of-medetomidine-and-xylazine-contaminating-illicit-fentanyl-supply 2026-08-23T17:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/connecticut-officials-warn-of-medetomidine-and-xylazine-contaminating-illicit-fentanyl-supply 2026-08-23T17:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-pharmova-receives-us-fda-approval-for-new-isolator-based-fill-and-finish-line-at-spokane-facility 2026-08-23T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-pharmova-receives-us-fda-approval-for-new-isolator-based-fill-and-finish-line-at-spokane-facility 2026-08-23T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/zcchc4-boosts-replication-dependent-histone-mrna-translation-via-eif3-interaction 2026-08-23T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zcchc4-boosts-replication-dependent-histone-mrna-translation-via-eif3-interaction 2026-08-23T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/declining-childhood-vaccination-rates-drive-resurgence-of-measles-and-pneumonia-risk 2026-08-23T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/declining-childhood-vaccination-rates-drive-resurgence-of-measles-and-pneumonia-risk 2026-08-23T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-vaccine-paired-with-keytruda-shows-promise-against-melanoma-recurrence 2026-08-23T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-mrna-vaccine-paired-with-keytruda-shows-promise-against-melanoma-recurrence 2026-08-23T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/weight-regain-after-weight-loss-medication-linked-to-four-fold-rise-in-suicidal-thoughts 2026-08-23T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-regain-after-weight-loss-medication-linked-to-four-fold-rise-in-suicidal-thoughts 2026-08-23T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-ncb-to-launch-24-nationwide-anti-narcotics-drives-targeting-pharmaceutical-drug-diversion 2026-08-23T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-ncb-to-launch-24-nationwide-anti-narcotics-drives-targeting-pharmaceutical-drug-diversion 2026-08-23T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/doctors-achieve-landmark-recoveries-with-haplo-cord-transplant-and-dual-target-car-t-cell-therapy 2026-08-23T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doctors-achieve-landmark-recoveries-with-haplo-cord-transplant-and-dual-target-car-t-cell-therapy 2026-08-23T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/two-year-trial-finds-mediterranean-style-diet-matches-weight-watchers-for-weight-loss-while-improving-diet-quality 2026-08-23T09:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-year-trial-finds-mediterranean-style-diet-matches-weight-watchers-for-weight-loss-while-improving-diet-quality 2026-08-23T09:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/more-than-18000-questionable-images-found-in-antibody-catalogues-of-15-companies 2026-08-23T09:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/more-than-18000-questionable-images-found-in-antibody-catalogues-of-15-companies 2026-08-23T09:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-treatment-shrinks-rare-thyroid-cancer-tumours-by-60-inspiring-patient-s-charity-ride 2026-08-23T07:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-treatment-shrinks-rare-thyroid-cancer-tumours-by-60-inspiring-patient-s-charity-ride 2026-08-23T07:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/china-builds-world-s-first-custom-plant-immunity-system-for-epidemic-response 2026-08-23T06:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-builds-world-s-first-custom-plant-immunity-system-for-epidemic-response 2026-08-23T06:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/officials-warn-wildland-firefighters-about-unproven-glutathione-supplement-for-smoke-exposure 2026-08-23T05:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/officials-warn-wildland-firefighters-about-unproven-glutathione-supplement-for-smoke-exposure 2026-08-23T05:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/india-restricts-cold-medicines-for-children-under-four-over-safety-concerns 2026-08-23T02:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-restricts-cold-medicines-for-children-under-four-over-safety-concerns 2026-08-23T02:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/children-at-the-centre-of-nigeria-s-worsening-drug-crisis 2026-08-23T01:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-at-the-centre-of-nigeria-s-worsening-drug-crisis 2026-08-23T01:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/orum-therapeutics-announces-u-s-fda-clearance-of-ind-for-orm-1153-a-first-in-class-cd123-gspt1-degrader-antibody-conjugate 2026-08-23T01:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orum-therapeutics-announces-u-s-fda-clearance-of-ind-for-orm-1153-a-first-in-class-cd123-gspt1-degrader-antibody-conjugate 2026-08-23T01:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/assam-achieves-world-s-first-ivf-born-lakhimi-calf-a-milestone-in-indigenous-cattle-conservation 2026-08-23T00:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assam-achieves-world-s-first-ivf-born-lakhimi-calf-a-milestone-in-indigenous-cattle-conservation 2026-08-23T00:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-and-medigen-vaccine-biologics-partner-to-advance-next-generation-multivalent-enterovirus-vaccine 2026-08-23T00:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-and-medigen-vaccine-biologics-partner-to-advance-next-generation-multivalent-enterovirus-vaccine 2026-08-23T00:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/ankle-co-contraction-explains-why-walking-becomes-harder-with-age-study-finds 2026-08-22T22:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankle-co-contraction-explains-why-walking-becomes-harder-with-age-study-finds 2026-08-22T22:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/mobility-tests-offer-valuable-insights-into-healthy-aging-but-they-are-not-a-crystal-ball 2026-08-22T21:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobility-tests-offer-valuable-insights-into-healthy-aging-but-they-are-not-a-crystal-ball 2026-08-22T21:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/utoledo-college-of-pharmacy-welcomes-largest-pharm-d-class-in-five-years 2026-08-22T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utoledo-college-of-pharmacy-welcomes-largest-pharm-d-class-in-five-years 2026-08-22T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/uk-plans-national-rollout-of-libido-suppressing-drugs-for-sex-offenders-by-december-2028 2026-08-22T18:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-plans-national-rollout-of-libido-suppressing-drugs-for-sex-offenders-by-december-2028 2026-08-22T18:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/international-overdose-awareness-day-marks-25th-year-as-health-systems-expand-naloxone-access-and-harm-reduction 2026-08-22T18:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-overdose-awareness-day-marks-25th-year-as-health-systems-expand-naloxone-access-and-harm-reduction 2026-08-22T18:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-lower-tuberculosis-risk-in-type-2-diabetes 2026-08-22T18:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-lower-tuberculosis-risk-in-type-2-diabetes 2026-08-22T18:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/eortc-perspective-urges-patient-preferences-as-clinical-trial-endpoints-in-geriatric-oncology 2026-08-22T18:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eortc-perspective-urges-patient-preferences-as-clinical-trial-endpoints-in-geriatric-oncology 2026-08-22T18:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-therapeutics-advances-oncology-immunotherapy-pipeline-ahead-of-september-healthcare-conferences 2026-08-22T17:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-therapeutics-advances-oncology-immunotherapy-pipeline-ahead-of-september-healthcare-conferences 2026-08-22T17:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/urolithin-a-a-gut-derived-postbiotic-improves-heart-function-in-hfpef-models-by-targeting-pkgia 2026-08-22T16:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urolithin-a-a-gut-derived-postbiotic-improves-heart-function-in-hfpef-models-by-targeting-pkgia 2026-08-22T16:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/gillette-acquires-south-boston-life-science-site-for-99-29m-pledges-near-1b-investment 2026-08-22T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gillette-acquires-south-boston-life-science-site-for-99-29m-pledges-near-1b-investment 2026-08-22T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-s-stream-platform-condenses-sepsis-diagnosis-from-days-to-hours 2026-08-22T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-state-s-stream-platform-condenses-sepsis-diagnosis-from-days-to-hours 2026-08-22T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-decodes-the-hidden-on-switch-behind-human-gene-activation 2026-08-22T15:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-decodes-the-hidden-on-switch-behind-human-gene-activation 2026-08-22T15:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-establishes-new-clinical-manufacturing-facility-in-slovenia-to-accelerate-biological-drug-development 2026-08-22T13:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-establishes-new-clinical-manufacturing-facility-in-slovenia-to-accelerate-biological-drug-development 2026-08-22T13:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/assam-s-amch-launches-rare-disease-treatment-as-centre-of-excellence-15-patients-begin-care-on-first-day 2026-08-22T12:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assam-s-amch-launches-rare-disease-treatment-as-centre-of-excellence-15-patients-begin-care-on-first-day 2026-08-22T12:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/new-oak-ridge-lab-accelerates-actinium-225-supply-for-next-generation-cancer-therapies 2026-08-22T11:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-oak-ridge-lab-accelerates-actinium-225-supply-for-next-generation-cancer-therapies 2026-08-22T11:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-appoints-wes-burwell-as-chief-human-resources-officer-to-support-commercialization-push 2026-08-22T09:53:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-appoints-wes-burwell-as-chief-human-resources-officer-to-support-commercialization-push 2026-08-22T09:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/kacey-musgraves-and-medicine-mama-launch-drought-drops-intimate-wellness-product 2026-08-22T09:50:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kacey-musgraves-and-medicine-mama-launch-drought-drops-intimate-wellness-product 2026-08-22T09:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-receives-usfda-approval-for-ascorbic-acid-injection-with-180-day-cgt-exclusivity 2026-08-22T09:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-receives-usfda-approval-for-ascorbic-acid-injection-with-180-day-cgt-exclusivity 2026-08-22T09:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-cdsco-expert-committee-recommends-local-trial-waivers-for-generic-lenacapavir-as-hiv-prep 2026-08-22T08:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-cdsco-expert-committee-recommends-local-trial-waivers-for-generic-lenacapavir-as-hiv-prep 2026-08-22T08:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-circular-rnas-emerge-as-a-breakthrough-early-diagnostic-tool-for-alzheimer-s-disease 2026-08-22T07:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-circular-rnas-emerge-as-a-breakthrough-early-diagnostic-tool-for-alzheimer-s-disease 2026-08-22T07:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/outer-biosciences-trains-ai-on-living-human-skin-to-accelerate-skincare-ingredient-discovery 2026-08-22T07:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outer-biosciences-trains-ai-on-living-human-skin-to-accelerate-skincare-ingredient-discovery 2026-08-22T07:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-s-therapeutic-promise-and-peril-a-cautionary-tale-of-unsupervised-use 2026-08-22T07:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketamine-s-therapeutic-promise-and-peril-a-cautionary-tale-of-unsupervised-use 2026-08-22T07:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/massachusetts-woman-sentenced-to-two-years-for-selling-body-parts-stolen-from-harvard-medical-school-morgue 2026-08-22T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massachusetts-woman-sentenced-to-two-years-for-selling-body-parts-stolen-from-harvard-medical-school-morgue 2026-08-22T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/reinforcement-learning-framework-fine-tunes-flow-matching-models-for-controllable-3d-drug-design 2026-08-22T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reinforcement-learning-framework-fine-tunes-flow-matching-models-for-controllable-3d-drug-design 2026-08-22T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/identification-and-characterization-of-mitochondrial-e3-ubiquitin-protein-ligase-1-mul1-in-disease-regulation 2026-08-21T23:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/identification-and-characterization-of-mitochondrial-e3-ubiquitin-protein-ligase-1-mul1-in-disease-regulation 2026-08-21T23:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/child-diagnosed-with-tuberculosis-at-launceston-childcare-centre-prompts-precautionary-testing 2026-08-21T22:55:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/child-diagnosed-with-tuberculosis-at-launceston-childcare-centre-prompts-precautionary-testing 2026-08-21T22:55:08+00:00 hourly 0.9 https://trial.medpath.com/news/eight-month-old-becomes-first-in-world-to-receive-precision-medicine-for-kcnt1-related-catastrophic-epilepsy 2026-08-21T22:54:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-month-old-becomes-first-in-world-to-receive-precision-medicine-for-kcnt1-related-catastrophic-epilepsy 2026-08-21T22:54:11+00:00 hourly 0.9 https://trial.medpath.com/news/capillaries-not-arteries-drive-formation-of-the-heart-s-natural-bypass-vessels 2026-08-21T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capillaries-not-arteries-drive-formation-of-the-heart-s-natural-bypass-vessels 2026-08-21T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-merck-mrna-cancer-therapy-hits-primary-endpoint-sending-biotech-stocks-to-post-pandemic-highs 2026-08-21T21:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-merck-mrna-cancer-therapy-hits-primary-endpoint-sending-biotech-stocks-to-post-pandemic-highs 2026-08-21T21:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-launches-first-ever-national-autism-missing-and-endangered-person-alert-initiative 2026-08-21T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-launches-first-ever-national-autism-missing-and-endangered-person-alert-initiative 2026-08-21T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-employer-health-care-costs-projected-to-rise-9-5-in-2027-marking-fourth-consecutive-year-of-near-double-digit-growth 2026-08-21T21:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-employer-health-care-costs-projected-to-rise-9-5-in-2027-marking-fourth-consecutive-year-of-near-double-digit-growth 2026-08-21T21:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/dsm-firmenich-initiates-patent-infringement-litigation-in-china-over-biotech-sclareol-production 2026-08-21T19:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsm-firmenich-initiates-patent-infringement-litigation-in-china-over-biotech-sclareol-production 2026-08-21T19:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/blood-collection-devices-market-to-reach-15-88-billion-by-2034-as-chronic-disease-testing-surges 2026-08-21T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-collection-devices-market-to-reach-15-88-billion-by-2034-as-chronic-disease-testing-surges 2026-08-21T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-uncover-molecular-switch-driving-triple-negative-breast-cancer-metastasis-pointing-to-cdk4-6-inhibitor-repurposing 2026-08-21T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-uncover-molecular-switch-driving-triple-negative-breast-cancer-metastasis-pointing-to-cdk4-6-inhibitor-repurposing 2026-08-21T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/chemotherapy-free-four-drug-regimen-yields-97-clinical-benefit-in-her2-positive-hr-positive-metastatic-breast-cancer 2026-08-21T16:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemotherapy-free-four-drug-regimen-yields-97-clinical-benefit-in-her2-positive-hr-positive-metastatic-breast-cancer 2026-08-21T16:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/younger-lung-cancer-patients-show-more-targetable-gene-alterations-supporting-broader-genomic-profiling 2026-08-21T16:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/younger-lung-cancer-patients-show-more-targetable-gene-alterations-supporting-broader-genomic-profiling 2026-08-21T16:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/when-ai-designs-a-drug-who-gets-the-credit-the-legal-wrinkle-in-ai-driven-drug-discovery 2026-08-21T15:51:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/when-ai-designs-a-drug-who-gets-the-credit-the-legal-wrinkle-in-ai-driven-drug-discovery 2026-08-21T15:51:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-wins-iso-13485-certification-opening-international-markets-for-onerf-ablation-platforms 2026-08-21T15:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroone-wins-iso-13485-certification-opening-international-markets-for-onerf-ablation-platforms 2026-08-21T15:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/carrie-ann-inaba-partners-with-novartis-to-raise-sjogren-s-disease-awareness 2026-08-21T15:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carrie-ann-inaba-partners-with-novartis-to-raise-sjogren-s-disease-awareness 2026-08-21T15:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/werewolf-and-ambros-therapeutics-announce-merger-to-advance-neridronate-as-potential-first-fda-approved-treatment-for-crps-1 2026-08-21T13:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/werewolf-and-ambros-therapeutics-announce-merger-to-advance-neridronate-as-potential-first-fda-approved-treatment-for-crps-1 2026-08-21T13:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-advances-therapeutic-mrna-vaccine-ly01620-into-phase-ii-for-hpv16-positive-cervical-lesions 2026-08-21T13:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luye-pharma-advances-therapeutic-mrna-vaccine-ly01620-into-phase-ii-for-hpv16-positive-cervical-lesions 2026-08-21T13:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/digital-empower-program-reduces-anxiety-and-depression-in-adults-with-chronic-conditions-with-self-directed-delivery-matching-human-supported-outcomes 2026-08-21T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-empower-program-reduces-anxiety-and-depression-in-adults-with-chronic-conditions-with-self-directed-delivery-matching-human-supported-outcomes 2026-08-21T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/men-with-heart-disease-face-higher-risk-of-developing-and-dying-from-cancer-25-year-study-finds 2026-08-21T13:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/men-with-heart-disease-face-higher-risk-of-developing-and-dying-from-cancer-25-year-study-finds 2026-08-21T13:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/ai-predicts-vaccine-response-before-vaccination-using-pre-existing-antibody-patterns 2026-08-21T13:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-predicts-vaccine-response-before-vaccination-using-pre-existing-antibody-patterns 2026-08-21T13:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/blood-protein-biomarkers-b2m-and-cystatin-c-predict-future-disability-in-very-old-adults 2026-08-21T12:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-protein-biomarkers-b2m-and-cystatin-c-predict-future-disability-in-very-old-adults 2026-08-21T12:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/curegene-doses-first-participant-in-phase-i-trial-of-oral-liver-targeting-thr-b-agonist-cg-0416 2026-08-21T12:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curegene-doses-first-participant-in-phase-i-trial-of-oral-liver-targeting-thr-b-agonist-cg-0416 2026-08-21T12:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-personalized-mrna-cancer-therapy-sector-accelerates-as-lk101-advances-toward-clinical-validation 2026-08-21T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-personalized-mrna-cancer-therapy-sector-accelerates-as-lk101-advances-toward-clinical-validation 2026-08-21T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/orphan-gpcr-gpr52-governs-collective-invasion-and-multicellular-organization-in-breast-cancer 2026-08-21T10:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphan-gpcr-gpr52-governs-collective-invasion-and-multicellular-organization-in-breast-cancer 2026-08-21T10:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-approves-revised-national-biotechnology-policy-2026-to-advance-research-and-commercialisation 2026-08-21T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-approves-revised-national-biotechnology-policy-2026-to-advance-research-and-commercialisation 2026-08-21T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/propionyl-coa-drives-cholesterol-production-and-hormone-therapy-resistance-in-prostate-cancer-weill-cornell-study-finds 2026-08-21T09:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propionyl-coa-drives-cholesterol-production-and-hormone-therapy-resistance-in-prostate-cancer-weill-cornell-study-finds 2026-08-21T09:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/antiseizure-medication-choice-alters-stroke-and-bleeding-risk-in-epilepsy-patients-on-doacs 2026-08-21T09:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antiseizure-medication-choice-alters-stroke-and-bleeding-risk-in-epilepsy-patients-on-doacs 2026-08-21T09:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market-for-gerd-treatment 2026-08-21T07:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market-for-gerd-treatment 2026-08-21T07:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-find-possible-new-route-to-more-powerful-mrna-drugs 2026-08-21T05:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-find-possible-new-route-to-more-powerful-mrna-drugs 2026-08-21T05:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/python-named-jodie-foster-becomes-first-snake-to-receive-pioneering-electrochemotherapy-cancer-treatment 2026-08-21T04:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/python-named-jodie-foster-becomes-first-snake-to-receive-pioneering-electrochemotherapy-cancer-treatment 2026-08-21T04:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/oklahoma-heart-institute-brings-national-cardiovascular-clinical-trials-to-tulsa 2026-08-21T04:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oklahoma-heart-institute-brings-national-cardiovascular-clinical-trials-to-tulsa 2026-08-21T04:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-guojian-posts-95-profit-surge-as-two-autoimmune-antibodies-win-nmpa-approval 2026-08-21T02:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-guojian-posts-95-profit-surge-as-two-autoimmune-antibodies-win-nmpa-approval 2026-08-21T02:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-two-homegrown-long-acting-rsv-antibodies-for-infants-challenging-beyfortus 2026-08-21T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-two-homegrown-long-acting-rsv-antibodies-for-infants-challenging-beyfortus 2026-08-21T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-secures-125-million-non-dilutive-financing-against-mazdutide-royalties 2026-08-21T01:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-secures-125-million-non-dilutive-financing-against-mazdutide-royalties 2026-08-21T01:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/multi-organ-chip-uncovers-key-mechanisms-behind-cancer-metastasis 2026-08-21T01:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-organ-chip-uncovers-key-mechanisms-behind-cancer-metastasis 2026-08-21T01:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/dll3-targeted-therapies-market-poised-to-exceed-2-billion-by-2030-as-combination-strategies-accelerate 2026-08-21T01:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dll3-targeted-therapies-market-poised-to-exceed-2-billion-by-2030-as-combination-strategies-accelerate 2026-08-21T01:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/fronteo-and-science-tokyo-launch-ai-drug-discovery-ecosystem-collaborative-research-cluster 2026-08-21T01:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fronteo-and-science-tokyo-launch-ai-drug-discovery-ecosystem-collaborative-research-cluster 2026-08-21T01:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeat-powered-battery-free-pacemaker-could-last-a-lifetime 2026-08-20T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeat-powered-battery-free-pacemaker-could-last-a-lifetime 2026-08-20T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-2-million-to-virginia-tech-virologist-to-decode-how-infected-cells-decide-to-live-or-die 2026-08-20T22:53:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-2-million-to-virginia-tech-virologist-to-decode-how-infected-cells-decide-to-live-or-die 2026-08-20T22:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/superbrewed-food-launches-thryvia-a-shelf-stable-protein-derived-postbiotic-for-gut-and-immune-health 2026-08-20T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/superbrewed-food-launches-thryvia-a-shelf-stable-protein-derived-postbiotic-for-gut-and-immune-health 2026-08-20T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/time-restricted-eating-lowers-blood-sugar-in-adults-with-type-1-diabetes-without-raising-safety-risks 2026-08-20T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/time-restricted-eating-lowers-blood-sugar-in-adults-with-type-1-diabetes-without-raising-safety-risks 2026-08-20T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-brain-penetrant-nlrp3-inhibitor-aci-19764-shows-safety-and-csf-exposure-in-first-in-human-study 2026-08-20T21:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-s-brain-penetrant-nlrp3-inhibitor-aci-19764-shows-safety-and-csf-exposure-in-first-in-human-study 2026-08-20T21:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/apec-economies-advance-genome-editing-and-biotechnology-to-strengthen-food-security 2026-08-20T21:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apec-economies-advance-genome-editing-and-biotechnology-to-strengthen-food-security 2026-08-20T21:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/def-leppard-s-vivian-campbell-reveals-hodgkin-lymphoma-relapse-after-donor-transplant 2026-08-20T21:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/def-leppard-s-vivian-campbell-reveals-hodgkin-lymphoma-relapse-after-donor-transplant 2026-08-20T21:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-pharmaceuticals-secures-world-first-approval-for-nanocarrier-entrapped-vitamin-d3-oral-dispersion 2026-08-20T21:50:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-pharmaceuticals-secures-world-first-approval-for-nanocarrier-entrapped-vitamin-d3-oral-dispersion 2026-08-20T21:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-and-institut-pasteur-sign-strategic-research-collaboration-to-advance-mrna-vaccines-for-infectious-diseases 2026-08-20T21:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-and-institut-pasteur-sign-strategic-research-collaboration-to-advance-mrna-vaccines-for-infectious-diseases 2026-08-20T21:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/ukzn-s-tricia-naicker-honored-for-pioneering-antimicrobial-resistance-drug-discovery 2026-08-20T21:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ukzn-s-tricia-naicker-honored-for-pioneering-antimicrobial-resistance-drug-discovery 2026-08-20T21:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/adaptin-bio-opens-enrollment-in-phase-1-trial-of-aptn-101-for-egfrviii-positive-glioblastoma 2026-08-20T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptin-bio-opens-enrollment-in-phase-1-trial-of-aptn-101-for-egfrviii-positive-glioblastoma 2026-08-20T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/varmx-enrolls-first-participant-in-global-phase-3-equilibrix-s-trial-of-vmx-c001-for-urgent-surgery 2026-08-20T19:51:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varmx-enrolls-first-participant-in-global-phase-3-equilibrix-s-trial-of-vmx-c001-for-urgent-surgery 2026-08-20T19:51:07+00:00 hourly 0.9 https://trial.medpath.com/news/splash-beverage-group-rebrands-as-endovia-health-sciences-pivoting-to-cannabinoid-pharmaceuticals 2026-08-20T19:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splash-beverage-group-rebrands-as-endovia-health-sciences-pivoting-to-cannabinoid-pharmaceuticals 2026-08-20T19:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/ovarian-aging-emerges-as-a-central-driver-of-women-s-health-span 2026-08-20T19:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovarian-aging-emerges-as-a-central-driver-of-women-s-health-span 2026-08-20T19:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/wisconsin-seeks-public-input-on-allocating-874-million-in-opioid-settlement-funds 2026-08-20T18:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wisconsin-seeks-public-input-on-allocating-874-million-in-opioid-settlement-funds 2026-08-20T18:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/radioligand-therapy-market-projected-to-reach-15-85-billion-by-2035-as-alpha-emitter-pipeline-matures 2026-08-20T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radioligand-therapy-market-projected-to-reach-15-85-billion-by-2035-as-alpha-emitter-pipeline-matures 2026-08-20T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/right-to-try-vs-expanded-access-examining-the-regulatory-claims-behind-a-high-profile-cancer-survival-story 2026-08-20T17:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/right-to-try-vs-expanded-access-examining-the-regulatory-claims-behind-a-high-profile-cancer-survival-story 2026-08-20T17:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-syndrome-emerges-rapidly-in-first-year-of-adt-arpi-therapy-for-prostate-cancer 2026-08-20T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-syndrome-emerges-rapidly-in-first-year-of-adt-arpi-therapy-for-prostate-cancer 2026-08-20T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/ictriplex-triplet-strategy-achieves-47-9-complete-remission-in-advanced-refractory-malignancies 2026-08-20T17:50:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ictriplex-triplet-strategy-achieves-47-9-complete-remission-in-advanced-refractory-malignancies 2026-08-20T17:50:07+00:00 hourly 0.9 https://trial.medpath.com/news/ild-day-2026-spotlights-precision-medicine-s-potential-to-transform-interstitial-lung-disease-care 2026-08-20T17:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ild-day-2026-spotlights-precision-medicine-s-potential-to-transform-interstitial-lung-disease-care 2026-08-20T17:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/astromech-raises-20m-to-build-ai-models-that-predict-evolutionary-change-reaching-3-8b-valuation 2026-08-20T17:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astromech-raises-20m-to-build-ai-models-that-predict-evolutionary-change-reaching-3-8b-valuation 2026-08-20T17:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-reverses-trump-era-ban-on-south-african-research-funding-reopening-hiv-and-tb-collaborations 2026-08-20T16:53:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-reverses-trump-era-ban-on-south-african-research-funding-reopening-hiv-and-tb-collaborations 2026-08-20T16:53:06+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-reports-first-human-case-of-eastern-equine-encephalitis-since-2021 2026-08-20T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-reports-first-human-case-of-eastern-equine-encephalitis-since-2021 2026-08-20T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-awards-31-1m-to-siemens-healthineers-for-autonomous-endovascular-stroke-robotics 2026-08-20T16:49:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arpa-h-awards-31-1m-to-siemens-healthineers-for-autonomous-endovascular-stroke-robotics 2026-08-20T16:49:49+00:00 hourly 0.9 https://trial.medpath.com/news/epic-signals-a-shift-toward-patient-directed-ai-as-ehr-giant-weighs-direct-to-consumer-power 2026-08-20T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epic-signals-a-shift-toward-patient-directed-ai-as-ehr-giant-weighs-direct-to-consumer-power 2026-08-20T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rha-redensity-eye-for-undereye-hollowing-in-adults-22-and-older 2026-08-20T15:50:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rha-redensity-eye-for-undereye-hollowing-in-adults-22-and-older 2026-08-20T15:50:34+00:00 hourly 0.9 https://trial.medpath.com/news/geroscience-pioneer-nir-barzilai-pursues-repurposed-drugs-and-longevity-genes-to-extend-health-span 2026-08-20T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geroscience-pioneer-nir-barzilai-pursues-repurposed-drugs-and-longevity-genes-to-extend-health-span 2026-08-20T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-ceo-david-dodd-to-present-at-2026-georgia-life-sciences-summit-as-company-advances-mva-vaccine-and-oncology-pipeline 2026-08-20T15:49:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-ceo-david-dodd-to-present-at-2026-georgia-life-sciences-summit-as-company-advances-mva-vaccine-and-oncology-pipeline 2026-08-20T15:49:43+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-injection-due-to-zinc-oxide-particulate-contamination 2026-08-20T15:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-braun-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-injection-due-to-zinc-oxide-particulate-contamination 2026-08-20T15:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/everglade-adds-former-arpa-h-scientific-advisor-kate-teffer-to-expand-federal-health-research-capabilities 2026-08-20T15:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everglade-adds-former-arpa-h-scientific-advisor-kate-teffer-to-expand-federal-health-research-capabilities 2026-08-20T15:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/no-risk-free-nicotine-use-review-maps-biological-hierarchy-of-cardiovascular-harm-across-all-delivery-methods 2026-08-20T15:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/no-risk-free-nicotine-use-review-maps-biological-hierarchy-of-cardiovascular-harm-across-all-delivery-methods 2026-08-20T15:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-potency-assessment-for-active-immunotherapy-products 2026-08-20T14:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-potency-assessment-for-active-immunotherapy-products 2026-08-20T14:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/andrea-maier-s-precision-medicine-approach-aims-to-give-longevity-science-a-solid-evidence-base 2026-08-20T14:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andrea-maier-s-precision-medicine-approach-aims-to-give-longevity-science-a-solid-evidence-base 2026-08-20T14:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/creative-biolabs-expands-complement-assays-and-adds-immunology-microfluidic-capabilities-for-biotherapeutics-research 2026-08-20T13:51:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-biolabs-expands-complement-assays-and-adds-immunology-microfluidic-capabilities-for-biotherapeutics-research 2026-08-20T13:51:14+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-hospital-launches-canada-s-first-paediatric-olink-lab-advancing-precision-medicine-for-children 2026-08-20T13:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-hospital-launches-canada-s-first-paediatric-olink-lab-advancing-precision-medicine-for-children 2026-08-20T13:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-ptab-obviousness-rulings-against-10x-genomics-single-cell-sequencing-patents 2026-08-20T13:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-ptab-obviousness-rulings-against-10x-genomics-single-cell-sequencing-patents 2026-08-20T13:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/precision-for-medicine-names-amanda-owens-gm-of-biospecimen-solutions-to-expand-access-to-characterized-samples 2026-08-20T13:49:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-for-medicine-names-amanda-owens-gm-of-biospecimen-solutions-to-expand-access-to-characterized-samples 2026-08-20T13:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/cure-alzheimer-s-fund-appoints-stephanie-wasco-as-executive-vice-president-of-marketing-and-communications 2026-08-20T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cure-alzheimer-s-fund-appoints-stephanie-wasco-as-executive-vice-president-of-marketing-and-communications 2026-08-20T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/special-journal-issue-maps-global-cancer-epidemiology-and-charts-the-path-to-precision-prevention 2026-08-20T13:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/special-journal-issue-maps-global-cancer-epidemiology-and-charts-the-path-to-precision-prevention 2026-08-20T13:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/review-maps-path-from-foundation-models-to-accountable-clinical-ai-in-medical-imaging 2026-08-20T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/review-maps-path-from-foundation-models-to-accountable-clinical-ai-in-medical-imaging 2026-08-20T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/eyconis-initiates-first-in-human-trial-of-long-acting-anti-vegf-therapy-eyc-0305-in-treatment-naive-wet-amd 2026-08-20T12:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyconis-initiates-first-in-human-trial-of-long-acting-anti-vegf-therapy-eyc-0305-in-treatment-naive-wet-amd 2026-08-20T12:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-for-biosimilar-pegfilgrastim-cavoley 2026-08-20T12:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-for-biosimilar-pegfilgrastim-cavoley 2026-08-20T12:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-receives-us-fda-approval-for-fluticasone-propionate-nasal-spray 2026-08-20T12:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-receives-us-fda-approval-for-fluticasone-propionate-nasal-spray 2026-08-20T12:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-base-editing-therapies 2026-08-20T11:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-base-editing-therapies 2026-08-20T11:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/lucid-group-names-eric-muller-as-ceo-to-lead-next-phase-of-growth 2026-08-20T11:53:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lucid-group-names-eric-muller-as-ceo-to-lead-next-phase-of-growth 2026-08-20T11:53:20+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-tumorad-01-hits-mtd-endpoint-pivots-to-head-and-neck-cancer 2026-08-20T11:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-s-tumorad-01-hits-mtd-endpoint-pivots-to-head-and-neck-cancer 2026-08-20T11:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/medivir-reports-q2-2026-fostrox-phase-2-flex-hcc-underway-miv-711-expanded-into-perthes-disease 2026-08-20T11:51:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medivir-reports-q2-2026-fostrox-phase-2-flex-hcc-underway-miv-711-expanded-into-perthes-disease 2026-08-20T11:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/supercentenarians-harbor-abundant-cancer-killing-cd4-cytotoxic-t-cells-without-exhaustion 2026-08-20T11:51:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supercentenarians-harbor-abundant-cancer-killing-cd4-cytotoxic-t-cells-without-exhaustion 2026-08-20T11:51:02+00:00 hourly 0.9 https://trial.medpath.com/news/smart-cancer-drug-rk-251-activates-only-in-cancer-cells-offering-targeted-alternative-to-chemotherapy 2026-08-20T10:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-cancer-drug-rk-251-activates-only-in-cancer-cells-offering-targeted-alternative-to-chemotherapy 2026-08-20T10:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-secures-eur13-26-million-series-b-to-advance-spatial-mapping-of-cell-surface-proteins 2026-08-20T10:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-secures-eur13-26-million-series-b-to-advance-spatial-mapping-of-cell-surface-proteins 2026-08-20T10:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/gubra-advances-obesity-pipeline-as-abbvie-and-boehringer-ingelheim-programs-reach-phase-2 2026-08-20T10:03:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gubra-advances-obesity-pipeline-as-abbvie-and-boehringer-ingelheim-programs-reach-phase-2 2026-08-20T10:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/alpk3-gene-therapy-reverses-severe-childhood-cardiomyopathy-in-mouse-and-human-models 2026-08-20T10:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpk3-gene-therapy-reverses-severe-childhood-cardiomyopathy-in-mouse-and-human-models 2026-08-20T10:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-completes-dosing-in-phase-1b-human-challenge-trial-of-oral-norovirus-antiviral-cdi-988 2026-08-20T10:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-completes-dosing-in-phase-1b-human-challenge-trial-of-oral-norovirus-antiviral-cdi-988 2026-08-20T10:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-of-its-kind-robotic-blood-draw-device-aletta 2026-08-20T10:01:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-of-its-kind-robotic-blood-draw-device-aletta 2026-08-20T10:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-highlights-unmc-s-biocontainment-preparedness-and-nutrition-education-initiatives-during-nebraska-visit 2026-08-20T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-highlights-unmc-s-biocontainment-preparedness-and-nutrition-education-initiatives-during-nebraska-visit 2026-08-20T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-reports-sharp-revenue-decline-and-widening-losses-in-h1-2025-amid-oncology-pipeline-push 2026-08-20T05:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-reports-sharp-revenue-decline-and-widening-losses-in-h1-2025-amid-oncology-pipeline-push 2026-08-20T05:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/combined-calcium-ionophore-and-pentoxifylline-improve-embryo-quality-in-dual-gamete-deficiency-mouse-model 2026-08-20T05:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combined-calcium-ionophore-and-pentoxifylline-improve-embryo-quality-in-dual-gamete-deficiency-mouse-model 2026-08-20T05:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/colorectal-tumors-may-damage-peripheral-nerves-before-chemotherapy-begins 2026-08-20T03:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorectal-tumors-may-damage-peripheral-nerves-before-chemotherapy-begins 2026-08-20T03:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/surprise-discovery-a-known-tb-gene-springs-to-action-under-stress-revealing-a-new-drug-target 2026-08-20T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surprise-discovery-a-known-tb-gene-springs-to-action-under-stress-revealing-a-new-drug-target 2026-08-20T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/cuh-chief-executive-warns-hospital-is-unsafe-for-patients-amid-over-1000-staff-shortfall 2026-08-20T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuh-chief-executive-warns-hospital-is-unsafe-for-patients-amid-over-1000-staff-shortfall 2026-08-20T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/host-defense-launches-immune-whole-body-support-a-functional-mushroom-supplement-for-dogs-and-cats 2026-08-20T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/host-defense-launches-immune-whole-body-support-a-functional-mushroom-supplement-for-dogs-and-cats 2026-08-20T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/neoimmunetech-licenses-il-7-therapy-nt-i7-to-tolerance-bio-in-deal-worth-up-to-260-million 2026-08-20T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoimmunetech-licenses-il-7-therapy-nt-i7-to-tolerance-bio-in-deal-worth-up-to-260-million 2026-08-20T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-ultragenyx-s-genglycos-first-gene-therapy-for-glycogen-storage-disease-type-ia 2026-08-20T01:24:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-ultragenyx-s-genglycos-first-gene-therapy-for-glycogen-storage-disease-type-ia 2026-08-20T01:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/digital-integrative-medicine-program-improves-overall-survival-in-patients-undergoing-systemic-cancer-treatment 2026-08-20T01:24:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-integrative-medicine-program-improves-overall-survival-in-patients-undergoing-systemic-cancer-treatment 2026-08-20T01:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-brain-organoids-with-distinct-cortical-regional-identity-to-study-fragile-x-syndrome 2026-08-20T01:22:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-brain-organoids-with-distinct-cortical-regional-identity-to-study-fragile-x-syndrome 2026-08-20T01:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/apoe-stratified-gwas-uncovers-new-alzheimer-s-risk-loci-and-supports-a-priori-apoe-stratification-in-ad-trials 2026-08-20T01:22:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apoe-stratified-gwas-uncovers-new-alzheimer-s-risk-loci-and-supports-a-priori-apoe-stratification-in-ad-trials 2026-08-20T01:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-sues-geo-group-to-force-compliance-with-tuberculosis-investigation-at-aurora-ice-detention-center 2026-08-19T22:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-sues-geo-group-to-force-compliance-with-tuberculosis-investigation-at-aurora-ice-detention-center 2026-08-19T22:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-picks-white-house-aide-dr-heidi-overton-to-lead-fda 2026-08-19T20:55:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-picks-white-house-aide-dr-heidi-overton-to-lead-fda 2026-08-19T20:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-settles-patent-litigation-with-teva-securing-u-s-exclusivity-for-lupkynis-until-2036 2026-08-19T20:54:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurinia-settles-patent-litigation-with-teva-securing-u-s-exclusivity-for-lupkynis-until-2036 2026-08-19T20:54:57+00:00 hourly 0.9 https://trial.medpath.com/news/auragxp-secures-initial-seed-funding-and-expands-executive-leadership-to-advance-ai-native-life-sciences-platform 2026-08-19T19:49:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auragxp-secures-initial-seed-funding-and-expands-executive-leadership-to-advance-ai-native-life-sciences-platform 2026-08-19T19:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/delayed-sting-activation-strategy-enhances-antitumor-immunity-of-mrna-cancer-vaccines 2026-08-19T18:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delayed-sting-activation-strategy-enhances-antitumor-immunity-of-mrna-cancer-vaccines 2026-08-19T18:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/bacterial-antibiotic-gladiolin-disarms-candida-albicans-by-forcing-it-back-to-a-harmless-state 2026-08-19T18:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacterial-antibiotic-gladiolin-disarms-candida-albicans-by-forcing-it-back-to-a-harmless-state 2026-08-19T18:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/aaadv-2026-workshop-to-confront-the-hardest-questions-in-global-cancer-drug-development 2026-08-19T18:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aaadv-2026-workshop-to-confront-the-hardest-questions-in-global-cancer-drug-development 2026-08-19T18:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/mapping-b7-h3-across-the-tumour-microenvironment-reveals-vascular-and-myeloid-compartments-as-key-targets 2026-08-19T18:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mapping-b7-h3-across-the-tumour-microenvironment-reveals-vascular-and-myeloid-compartments-as-key-targets 2026-08-19T18:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/coregen-s-crispr-edited-treg-therapy-crg-150-advances-to-first-in-human-trial-in-breast-and-prostate-cancers 2026-08-19T18:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coregen-s-crispr-edited-treg-therapy-crg-150-advances-to-first-in-human-trial-in-breast-and-prostate-cancers 2026-08-19T18:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-selects-avance-clinical-as-cro-for-phase-2-3-titan-study-of-gemini-in-acute-kidney-injury 2026-08-19T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelation-biosciences-selects-avance-clinical-as-cro-for-phase-2-3-titan-study-of-gemini-in-acute-kidney-injury 2026-08-19T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/trump-nominates-heidi-overton-to-lead-the-fda 2026-08-19T18:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-nominates-heidi-overton-to-lead-the-fda 2026-08-19T18:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/arcato-s-arc-001-gel-meets-safety-endpoint-in-phase-1-trial-showing-durable-analgesia-after-third-molar-surgery 2026-08-19T18:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcato-s-arc-001-gel-meets-safety-endpoint-in-phase-1-trial-showing-durable-analgesia-after-third-molar-surgery 2026-08-19T18:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/new-post-exposure-covid-19-prevention-medicine-available-as-transmission-rises-nationwide 2026-08-19T18:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-post-exposure-covid-19-prevention-medicine-available-as-transmission-rises-nationwide 2026-08-19T18:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/jocasta-neuroscience-secures-direct-ucsf-license-for-a-klotho-clearing-path-to-2027-phase-i-trial 2026-08-19T18:14:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jocasta-neuroscience-secures-direct-ucsf-license-for-a-klotho-clearing-path-to-2027-phase-i-trial 2026-08-19T18:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-launches-bubblegen-cd3-t-cell-selection-kit-for-bead-free-cell-therapy-manufacturing 2026-08-19T18:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-launches-bubblegen-cd3-t-cell-selection-kit-for-bead-free-cell-therapy-manufacturing 2026-08-19T18:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/kynexis-extends-series-a-to-eur97-million-to-advance-first-in-class-kat-ii-inhibitor-for-cognitive-impairment-in-schizophrenia 2026-08-19T18:13:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kynexis-extends-series-a-to-eur97-million-to-advance-first-in-class-kat-ii-inhibitor-for-cognitive-impairment-in-schizophrenia 2026-08-19T18:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-clinic-360-gains-fda-510-k-clearance-for-cloud-based-ophthalmic-workflow-solution 2026-08-19T18:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-clinic-360-gains-fda-510-k-clearance-for-cloud-based-ophthalmic-workflow-solution 2026-08-19T18:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-launches-keelira-a-specialized-cro-for-european-phase-i-ii-oncology-development 2026-08-19T18:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-launches-keelira-a-specialized-cro-for-european-phase-i-ii-oncology-development 2026-08-19T18:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-announces-750-million-device-fill-finish-manufacturing-expansion-in-hillsboro-oregon 2026-08-19T18:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-announces-750-million-device-fill-finish-manufacturing-expansion-in-hillsboro-oregon 2026-08-19T18:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-announces-fda-approval-of-modular-pma-pathway-for-fembloc-non-surgical-permanent-birth-control 2026-08-19T18:12:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-announces-fda-approval-of-modular-pma-pathway-for-fembloc-non-surgical-permanent-birth-control 2026-08-19T18:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-s-stei-method-eliminates-sample-preparation-for-spatial-multiomics-analysis 2026-08-19T18:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-s-stei-method-eliminates-sample-preparation-for-spatial-multiomics-analysis 2026-08-19T18:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/the-exocrine-pancreas-emerges-as-a-critical-player-in-diabetes-pathophysiology-and-care 2026-08-19T18:11:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-exocrine-pancreas-emerges-as-a-critical-player-in-diabetes-pathophysiology-and-care 2026-08-19T18:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-mrna-patent-showdown-against-moderna-biontech-and-pfizer-opens-at-the-hague-upc 2026-08-19T18:11:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-mrna-patent-showdown-against-moderna-biontech-and-pfizer-opens-at-the-hague-upc 2026-08-19T18:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/international-task-force-outlines-roadmap-for-precision-stroke-recovery-using-molecular-biomarkers 2026-08-19T18:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-task-force-outlines-roadmap-for-precision-stroke-recovery-using-molecular-biomarkers 2026-08-19T18:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/indigo-light-may-prevent-and-treat-myopia-by-restoring-a-missing-wavelength-in-indoor-lighting 2026-08-19T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indigo-light-may-prevent-and-treat-myopia-by-restoring-a-missing-wavelength-in-indoor-lighting 2026-08-19T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/foresite-labs-appoints-dr-jorge-reis-filho-to-lead-ai-driven-biomedical-discovery-strategy 2026-08-19T18:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresite-labs-appoints-dr-jorge-reis-filho-to-lead-ai-driven-biomedical-discovery-strategy 2026-08-19T18:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/uvm-launches-tuition-free-biotechnology-technician-certificate-to-build-regional-life-sciences-workforce 2026-08-19T18:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uvm-launches-tuition-free-biotechnology-technician-certificate-to-build-regional-life-sciences-workforce 2026-08-19T18:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-unveils-global-brand-sbp-group-to-accelerate-international-expansion 2026-08-19T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-unveils-global-brand-sbp-group-to-accelerate-international-expansion 2026-08-19T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/network-bio-launches-with-50m-to-build-first-cell-free-rna-foundation-model-with-nvidia 2026-08-19T18:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-bio-launches-with-50m-to-build-first-cell-free-rna-foundation-model-with-nvidia 2026-08-19T18:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-self-assembling-dna-fragments-could-overcome-the-bottleneck-in-writing-long-complex-sequences 2026-08-19T13:51:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-self-assembling-dna-fragments-could-overcome-the-bottleneck-in-writing-long-complex-sequences 2026-08-19T13:51:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-deciphera-s-vimseltinib-romvimza-for-tenosynovial-giant-cell-tumour 2026-08-19T13:50:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-approves-deciphera-s-vimseltinib-romvimza-for-tenosynovial-giant-cell-tumour 2026-08-19T13:50:34+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-reports-2026-interim-results-serplulimab-becomes-first-anti-pd-1-mab-approved-for-perioperative-gastric-cancer 2026-08-19T12:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-reports-2026-interim-results-serplulimab-becomes-first-anti-pd-1-mab-approved-for-perioperative-gastric-cancer 2026-08-19T12:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/crescendo-health-appoints-david-strutton-phd-as-chief-scientific-officer 2026-08-19T12:52:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crescendo-health-appoints-david-strutton-phd-as-chief-scientific-officer 2026-08-19T12:52:26+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-medications-not-linked-to-higher-respiratory-adverse-event-risk-meta-analysis-finds 2026-08-19T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-medications-not-linked-to-higher-respiratory-adverse-event-risk-meta-analysis-finds 2026-08-19T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/patients-and-researchers-challenge-fda-approved-cancer-drug-dosages-citing-billions-in-potential-savings-and-avoidable-toxicity 2026-08-19T10:52:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patients-and-researchers-challenge-fda-approved-cancer-drug-dosages-citing-billions-in-potential-savings-and-avoidable-toxicity 2026-08-19T10:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-risk-score-identifies-hidden-type-1-diabetes-in-nearly-one-in-five-mody-referrals 2026-08-19T10:52:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-risk-score-identifies-hidden-type-1-diabetes-in-nearly-one-in-five-mody-referrals 2026-08-19T10:52:39+00:00 hourly 0.9 https://trial.medpath.com/news/norroy-bioscience-s-68ga-nym096-receives-fda-breakthrough-therapy-and-fast-track-designations-for-ccrcc-pet-imaging 2026-08-19T09:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norroy-bioscience-s-68ga-nym096-receives-fda-breakthrough-therapy-and-fast-track-designations-for-ccrcc-pet-imaging 2026-08-19T09:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-reports-16-cer-revenue-growth-in-h1-2026-driven-by-vyepti-and-advancing-pipeline 2026-08-19T08:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-reports-16-cer-revenue-growth-in-h1-2026-driven-by-vyepti-and-advancing-pipeline 2026-08-19T08:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-secures-first-gene-therapy-approval-and-priority-review-voucher-lifting-rare-stock-6-after-hours 2026-08-19T08:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-secures-first-gene-therapy-approval-and-priority-review-voucher-lifting-rare-stock-6-after-hours 2026-08-19T08:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/medication-mix-up-at-ascension-saint-thomas-hospital-midtown-leaves-72-year-old-woman-paralyzed-four-patients-harmed 2026-08-19T05:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medication-mix-up-at-ascension-saint-thomas-hospital-midtown-leaves-72-year-old-woman-paralyzed-four-patients-harmed 2026-08-19T05:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/laser-interstitial-thermal-therapy-extends-survival-in-glioblastoma-when-tumor-ablation-exceeds-91-and-treatment-occurs-early 2026-08-19T04:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laser-interstitial-thermal-therapy-extends-survival-in-glioblastoma-when-tumor-ablation-exceeds-91-and-treatment-occurs-early 2026-08-19T04:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-medical-school-agrees-to-53-million-settlement-over-morgue-body-parts-scandal 2026-08-19T02:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-medical-school-agrees-to-53-million-settlement-over-morgue-body-parts-scandal 2026-08-19T02:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/wellspring-consumer-healthcare-launches-seven-hypochlorous-acid-products-across-its-personal-care-portfolio 2026-08-19T02:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellspring-consumer-healthcare-launches-seven-hypochlorous-acid-products-across-its-personal-care-portfolio 2026-08-19T02:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/10x-health-advances-precision-nutrition-platform-expanding-internationally-through-m42-partnership-in-abu-dhabi 2026-08-19T01:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10x-health-advances-precision-nutrition-platform-expanding-internationally-through-m42-partnership-in-abu-dhabi 2026-08-19T01:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/uab-heersink-school-of-medicine-awards-inaugural-team-science-grants-to-tackle-complex-health-challenges 2026-08-19T01:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-heersink-school-of-medicine-awards-inaugural-team-science-grants-to-tackle-complex-health-challenges 2026-08-19T01:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-s-al001-lithium-imaging-data-accepted-for-oral-presentation-at-ismrm-x-nuclei-workshop 2026-08-19T01:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzamend-neuro-s-al001-lithium-imaging-data-accepted-for-oral-presentation-at-ismrm-x-nuclei-workshop 2026-08-19T01:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/how-decades-of-publicly-funded-biomedical-research-translate-into-patient-care 2026-08-19T00:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-decades-of-publicly-funded-biomedical-research-translate-into-patient-care 2026-08-19T00:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/curavit-acquires-lindus-health-cro-assets-to-expand-global-clinical-trial-delivery-across-u-s-and-europe 2026-08-18T23:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curavit-acquires-lindus-health-cro-assets-to-expand-global-clinical-trial-delivery-across-u-s-and-europe 2026-08-18T23:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/federal-and-industry-sponsors-play-complementary-roles-in-us-cancer-clinical-trials-with-drug-costs-reaching-millions 2026-08-18T22:57:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-and-industry-sponsors-play-complementary-roles-in-us-cancer-clinical-trials-with-drug-costs-reaching-millions 2026-08-18T22:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/hodgkin-lymphoma-survivors-face-nearly-twice-the-mortality-of-the-general-population 2026-08-18T22:56:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hodgkin-lymphoma-survivors-face-nearly-twice-the-mortality-of-the-general-population 2026-08-18T22:56:48+00:00 hourly 0.9 https://trial.medpath.com/news/kratom-poison-center-reports-climb-from-19-to-1242-in-13-years-as-severe-outcomes-surge 2026-08-18T22:56:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kratom-poison-center-reports-climb-from-19-to-1242-in-13-years-as-severe-outcomes-surge 2026-08-18T22:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/celine-dion-details-intensive-rehabilitation-and-immunotherapy-regimen-in-battle-against-stiff-person-syndrome 2026-08-18T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celine-dion-details-intensive-rehabilitation-and-immunotherapy-regimen-in-battle-against-stiff-person-syndrome 2026-08-18T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-clarifying-when-to-submit-an-anda-versus-a-505-b-2-application 2026-08-18T22:56:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-clarifying-when-to-submit-an-anda-versus-a-505-b-2-application 2026-08-18T22:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/halozyme-appoints-dannielle-appelhans-to-its-board-of-directors 2026-08-18T22:55:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halozyme-appoints-dannielle-appelhans-to-its-board-of-directors 2026-08-18T22:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/human-hearts-regrow-muscle-after-heart-attack-study-in-circulation-research-finds 2026-08-18T22:54:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-hearts-regrow-muscle-after-heart-attack-study-in-circulation-research-finds 2026-08-18T22:54:37+00:00 hourly 0.9 https://trial.medpath.com/news/aqua-medical-advances-pima-procedure-for-type-2-diabetes-with-first-west-coast-patient-and-new-ceo 2026-08-18T22:54:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aqua-medical-advances-pima-procedure-for-type-2-diabetes-with-first-west-coast-patient-and-new-ceo 2026-08-18T22:54:25+00:00 hourly 0.9 https://trial.medpath.com/news/karmanos-cancer-institute-hosts-fifth-annual-screening-saves-lives-event-to-boost-early-cancer-detection-in-detroit 2026-08-18T22:53:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karmanos-cancer-institute-hosts-fifth-annual-screening-saves-lives-event-to-boost-early-cancer-detection-in-detroit 2026-08-18T22:53:31+00:00 hourly 0.9 https://trial.medpath.com/news/roche-canada-and-pcpa-complete-negotiations-for-perjeta-in-neoadjuvant-her2-positive-early-breast-cancer 2026-08-18T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-canada-and-pcpa-complete-negotiations-for-perjeta-in-neoadjuvant-her2-positive-early-breast-cancer 2026-08-18T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-sets-out-regulatory-pathway-for-microbiome-based-medicinal-products 2026-08-18T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-sets-out-regulatory-pathway-for-microbiome-based-medicinal-products 2026-08-18T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/acanthamoeba-encephalitis-in-chronic-lymphocytic-leukemia-case-report-highlights-infection-risk-with-ibrutinib 2026-08-18T19:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acanthamoeba-encephalitis-in-chronic-lymphocytic-leukemia-case-report-highlights-infection-risk-with-ibrutinib 2026-08-18T19:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/genbio-ai-unveils-aido-cell-first-world-model-simulating-a-human-cell-across-the-full-biological-hierarchy 2026-08-18T19:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genbio-ai-unveils-aido-cell-first-world-model-simulating-a-human-cell-across-the-full-biological-hierarchy 2026-08-18T19:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/lynch-regenerative-medicine-completes-enrollment-in-phase-ii-trial-of-rhpdgf-bb-for-full-thickness-head-and-neck-wound-healing 2026-08-18T19:00:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lynch-regenerative-medicine-completes-enrollment-in-phase-ii-trial-of-rhpdgf-bb-for-full-thickness-head-and-neck-wound-healing 2026-08-18T19:00:44+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-partners-with-queen-s-university-to-manufacture-aav9-gm2-gene-therapy-for-gm2-gangliosidoses 2026-08-18T19:00:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-partners-with-queen-s-university-to-manufacture-aav9-gm2-gene-therapy-for-gm2-gangliosidoses 2026-08-18T19:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cortechs-ai-s-neuroquant-pet-for-quantitative-amyloid-imaging-in-cognitive-impairment 2026-08-18T18:59:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cortechs-ai-s-neuroquant-pet-for-quantitative-amyloid-imaging-in-cognitive-impairment 2026-08-18T18:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/caregiver-perspectives-shape-design-of-federally-funded-coach-trial-for-autism-coaching-at-home 2026-08-18T18:59:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caregiver-perspectives-shape-design-of-federally-funded-coach-trial-for-autism-coaching-at-home 2026-08-18T18:59:13+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-vaccine-critical-in-fight-against-infectious-disease-and-cancer 2026-08-18T17:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-vaccine-critical-in-fight-against-infectious-disease-and-cancer 2026-08-18T17:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-to-veeva-vault-crm-globally-advancing-ai-native-commercial-operations 2026-08-18T17:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-to-veeva-vault-crm-globally-advancing-ai-native-commercial-operations 2026-08-18T17:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-researchers-propose-mitochondrial-dysfunction-as-target-to-make-car-t-cell-therapy-safer 2026-08-18T17:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-irvine-researchers-propose-mitochondrial-dysfunction-as-target-to-make-car-t-cell-therapy-safer 2026-08-18T17:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-synthesis-raw-materials-market-to-surpass-usd-3-89-billion-by-2035 2026-08-18T17:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-synthesis-raw-materials-market-to-surpass-usd-3-89-billion-by-2035 2026-08-18T17:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/value-partners-insilico-medicine-and-shanghai-pudong-launch-ai-life-sciences-cvc-fund 2026-08-18T17:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/value-partners-insilico-medicine-and-shanghai-pudong-launch-ai-life-sciences-cvc-fund 2026-08-18T17:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-upholds-injunction-against-noviets-pharma-over-noviets-mark-citing-deceptive-similarity-to-novartis 2026-08-18T16:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-upholds-injunction-against-noviets-pharma-over-noviets-mark-citing-deceptive-similarity-to-novartis 2026-08-18T16:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-marks-10-years-of-immunology-scholarship-awarding-6-million-to-over-350-students 2026-08-18T15:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-marks-10-years-of-immunology-scholarship-awarding-6-million-to-over-350-students 2026-08-18T15:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/pm360-names-alex-gorsky-lifetime-achievement-honoree-and-lina-polimeni-cmo-of-the-year-for-2026-trailblazer-awards 2026-08-18T15:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pm360-names-alex-gorsky-lifetime-achievement-honoree-and-lina-polimeni-cmo-of-the-year-for-2026-trailblazer-awards 2026-08-18T15:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles 2026-08-18T15:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles 2026-08-18T15:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/ora-appoints-retina-specialist-dr-john-trein-as-therapeutic-lead-posterior 2026-08-18T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ora-appoints-retina-specialist-dr-john-trein-as-therapeutic-lead-posterior 2026-08-18T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-cancer-specialists-welcomes-lung-cancer-researcher-tina-roy-md-asco-young-investigator-award-honoree 2026-08-18T14:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-cancer-specialists-welcomes-lung-cancer-researcher-tina-roy-md-asco-young-investigator-award-honoree 2026-08-18T14:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-s-permeaderm-i-study-shows-70-cost-advantage-over-allograft-with-comparable-clinical-outcomes 2026-08-18T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-s-permeaderm-i-study-shows-70-cost-advantage-over-allograft-with-comparable-clinical-outcomes 2026-08-18T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-to-acquire-alesta-therapeutics-for-ale1-a-potential-first-oral-therapy-for-hypophosphatasia 2026-08-18T13:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-to-acquire-alesta-therapeutics-for-ale1-a-potential-first-oral-therapy-for-hypophosphatasia 2026-08-18T13:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/zyrtec-launches-drug-free-allergen-shield-spray-for-proactive-allergen-defense 2026-08-18T12:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyrtec-launches-drug-free-allergen-shield-spray-for-proactive-allergen-defense 2026-08-18T12:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/longevica-therapeutics-appoints-ex-genentech-veteran-dr-prasun-mishra-as-ceo-to-advance-world-s-largest-mammalian-longevity-study-toward-the-clinic 2026-08-18T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longevica-therapeutics-appoints-ex-genentech-veteran-dr-prasun-mishra-as-ceo-to-advance-world-s-largest-mammalian-longevity-study-toward-the-clinic 2026-08-18T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-drugmakers-slash-costs-as-generic-price-cuts-squeeze-r-d-budgets 2026-08-18T11:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-drugmakers-slash-costs-as-generic-price-cuts-squeeze-r-d-budgets 2026-08-18T11:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/abpi-sets-out-priorities-for-the-uk-s-health-data-research-service 2026-08-18T10:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpi-sets-out-priorities-for-the-uk-s-health-data-research-service 2026-08-18T10:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/why-drug-development-costs-are-rising-a-65-jump-in-a-decade 2026-08-18T10:47:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/why-drug-development-costs-are-rising-a-65-jump-in-a-decade 2026-08-18T10:47:50+00:00 hourly 0.9 https://trial.medpath.com/news/coultreon-biopharma-appoints-prista-charuworn-md-as-chief-medical-officer-to-advance-first-in-class-sik3-inhibitor-col-5671 2026-08-18T09:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coultreon-biopharma-appoints-prista-charuworn-md-as-chief-medical-officer-to-advance-first-in-class-sik3-inhibitor-col-5671 2026-08-18T09:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-up-to-435-million 2026-08-18T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-up-to-435-million 2026-08-18T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/deterrence-by-resilience-a-new-framework-for-securing-the-us-against-ai-enabled-biological-threats 2026-08-18T09:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deterrence-by-resilience-a-new-framework-for-securing-the-us-against-ai-enabled-biological-threats 2026-08-18T09:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/amygdala-neurosciences-announces-fda-clearance-of-ind-for-ans-858-a-first-in-class-aldh2-inhibitor 2026-08-18T07:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amygdala-neurosciences-announces-fda-clearance-of-ind-for-ans-858-a-first-in-class-aldh2-inhibitor 2026-08-18T07:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/nih-grant-funds-bu-study-of-lung-s-mosaic-alveolar-structure-and-its-impact-on-inhaled-particle-delivery 2026-08-18T06:47:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-grant-funds-bu-study-of-lung-s-mosaic-alveolar-structure-and-its-impact-on-inhaled-particle-delivery 2026-08-18T06:47:40+00:00 hourly 0.9 https://trial.medpath.com/news/openai-foundation-launches-public-data-for-health-funding-biotech-data-troves-for-ai-drug-discovery 2026-08-18T04:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openai-foundation-launches-public-data-for-health-funding-biotech-data-troves-for-ai-drug-discovery 2026-08-18T04:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/hayden-panettiere-heroes-and-nashville-actress-dies-at-36-preliminary-autopsy-finds-no-signs-of-trauma 2026-08-18T03:59:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hayden-panettiere-heroes-and-nashville-actress-dies-at-36-preliminary-autopsy-finds-no-signs-of-trauma 2026-08-18T03:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/craif-raises-33m-series-d-to-bring-urine-based-ai-cancer-test-to-the-u-s 2026-08-18T03:59:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/craif-raises-33m-series-d-to-bring-urine-based-ai-cancer-test-to-the-u-s 2026-08-18T03:59:05+00:00 hourly 0.9 https://trial.medpath.com/news/il-17-driven-inflammatory-program-reveals-immunotherapy-permissive-subtype-in-clear-cell-ovarian-cancer 2026-08-18T00:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-17-driven-inflammatory-program-reveals-immunotherapy-permissive-subtype-in-clear-cell-ovarian-cancer 2026-08-18T00:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/uranium-boom-revives-tribal-health-concerns-at-white-mesa-mill 2026-08-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uranium-boom-revives-tribal-health-concerns-at-white-mesa-mill 2026-08-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-launches-clinical-trial-search-portal-and-updated-registration-and-results-disclosure-guidance 2026-08-17T23:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-launches-clinical-trial-search-portal-and-updated-registration-and-results-disclosure-guidance 2026-08-17T23:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/giant-and-martin-s-pharmacies-now-offering-flu-and-pneumonia-vaccinations-ahead-of-flu-season 2026-08-17T22:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/giant-and-martin-s-pharmacies-now-offering-flu-and-pneumonia-vaccinations-ahead-of-flu-season 2026-08-17T22:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/meijer-expands-vaccine-access-with-new-schedule-ahead-feature-and-mobile-clinics-ahead-of-flu-season 2026-08-17T21:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meijer-expands-vaccine-access-with-new-schedule-ahead-feature-and-mobile-clinics-ahead-of-flu-season 2026-08-17T21:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/la-roche-posay-awards-50000-to-eight-early-career-dermatology-researchers-in-2025-young-investigator-grant 2026-08-17T19:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/la-roche-posay-awards-50000-to-eight-early-career-dermatology-researchers-in-2025-young-investigator-grant 2026-08-17T19:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/bgi-genomics-and-gortec-china-partner-to-advance-ctdna-mrd-and-multi-omics-in-precision-head-and-neck-cancer-care 2026-08-17T19:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bgi-genomics-and-gortec-china-partner-to-advance-ctdna-mrd-and-multi-omics-in-precision-head-and-neck-cancer-care 2026-08-17T19:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-unions-call-for-fast-track-approval-and-funding-of-rsv-vaccines-in-new-zealand 2026-08-17T18:50:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-unions-call-for-fast-track-approval-and-funding-of-rsv-vaccines-in-new-zealand 2026-08-17T18:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/uab-startup-nuvasc-advances-liquid-biopsy-precision-medicine-for-brain-arteriovenous-malformations 2026-08-17T17:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-startup-nuvasc-advances-liquid-biopsy-precision-medicine-for-brain-arteriovenous-malformations 2026-08-17T17:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/simple-scheduling-change-improves-health-and-well-being-of-night-shift-physicians 2026-08-17T17:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simple-scheduling-change-improves-health-and-well-being-of-night-shift-physicians 2026-08-17T17:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-rolls-out-trailblazing-lenacapavir-for-multi-drug-resistant-hiv 2026-08-17T17:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-rolls-out-trailblazing-lenacapavir-for-multi-drug-resistant-hiv 2026-08-17T17:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/computational-pipeline-uncovers-subtype-specific-adc-targets-for-cervical-cancer 2026-08-17T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/computational-pipeline-uncovers-subtype-specific-adc-targets-for-cervical-cancer 2026-08-17T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/sinovac-posts-12-9-revenue-growth-on-overseas-expansion-advances-late-stage-vaccine-pipeline 2026-08-17T16:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinovac-posts-12-9-revenue-growth-on-overseas-expansion-advances-late-stage-vaccine-pipeline 2026-08-17T16:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/running-paediatric-gene-therapy-studies-operations-and-oversight-in-practice 2026-08-17T16:52:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/running-paediatric-gene-therapy-studies-operations-and-oversight-in-practice 2026-08-17T16:52:17+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-engineers-immune-cells-to-follow-cancer-s-metabolic-scent 2026-08-17T16:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-engineers-immune-cells-to-follow-cancer-s-metabolic-scent 2026-08-17T16:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-red-blood-cell-vesicles-advance-gene-therapy-and-tumor-targeting-delivery 2026-08-17T16:51:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-red-blood-cell-vesicles-advance-gene-therapy-and-tumor-targeting-delivery 2026-08-17T16:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-macrophages-target-severe-bacterial-infections-without-genetic-modification 2026-08-17T16:51:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-macrophages-target-severe-bacterial-infections-without-genetic-modification 2026-08-17T16:51:05+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-elinzanetant-lynkuet-to-treat-hot-flashes-in-breast-cancer-patients 2026-08-17T16:50:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-elinzanetant-lynkuet-to-treat-hot-flashes-in-breast-cancer-patients 2026-08-17T16:50:49+00:00 hourly 0.9 https://trial.medpath.com/news/sbe-council-urges-cms-to-withdraw-ipay-2029-drug-price-negotiation-modification-citing-threat-to-biotech-innovation 2026-08-17T16:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sbe-council-urges-cms-to-withdraw-ipay-2029-drug-price-negotiation-modification-citing-threat-to-biotech-innovation 2026-08-17T16:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/fulcrum-and-slate-medicines-to-combine-in-reverse-merger-advancing-next-generation-migraine-therapies 2026-08-17T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulcrum-and-slate-medicines-to-combine-in-reverse-merger-advancing-next-generation-migraine-therapies 2026-08-17T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/first-federal-bellwether-trial-opens-against-mead-johnson-in-nec-infant-formula-mdl 2026-08-17T16:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-federal-bellwether-trial-opens-against-mead-johnson-in-nec-infant-formula-mdl 2026-08-17T16:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/aircrews-face-highest-proportion-of-radiation-related-cancer-deaths-among-503-u-s-occupations 2026-08-17T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aircrews-face-highest-proportion-of-radiation-related-cancer-deaths-among-503-u-s-occupations 2026-08-17T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/juvena-therapeutics-appoints-julie-anne-smith-as-ceo-as-juv-161-advances-through-phase-2a 2026-08-17T15:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juvena-therapeutics-appoints-julie-anne-smith-as-ceo-as-juv-161-advances-through-phase-2a 2026-08-17T15:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/prostate-cancer-screening-and-risk-stratified-treatment-updated-guidance-for-clinicians 2026-08-17T15:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prostate-cancer-screening-and-risk-stratified-treatment-updated-guidance-for-clinicians 2026-08-17T15:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/connext-completes-enrollment-in-phase-2-trial-of-cnt201-for-dupuytren-s-contracture 2026-08-17T15:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/connext-completes-enrollment-in-phase-2-trial-of-cnt201-for-dupuytren-s-contracture 2026-08-17T15:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-doses-first-patient-in-phase-1-trial-of-onc-783-first-in-class-t-cell-engager-targeting-neocd24 2026-08-17T15:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-doses-first-patient-in-phase-1-trial-of-onc-783-first-in-class-t-cell-engager-targeting-neocd24 2026-08-17T15:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/seton-hall-professor-awarded-national-grant-to-use-ai-and-virtual-reality-in-teaching-social-determinants-of-health 2026-08-17T15:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seton-hall-professor-awarded-national-grant-to-use-ai-and-virtual-reality-in-teaching-social-determinants-of-health 2026-08-17T15:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-rapidly-spreading-genetic-variants-driving-malaria-drug-resistance 2026-08-17T14:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-rapidly-spreading-genetic-variants-driving-malaria-drug-resistance 2026-08-17T14:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/webinar-to-examine-access-program-process-changes-for-faster-specialty-and-rare-disease-therapy 2026-08-17T13:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/webinar-to-examine-access-program-process-changes-for-faster-specialty-and-rare-disease-therapy 2026-08-17T13:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/eight-year-finnish-study-links-greater-childhood-screen-time-to-better-cognitive-processing-in-adolescence 2026-08-17T13:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-year-finnish-study-links-greater-childhood-screen-time-to-better-cognitive-processing-in-adolescence 2026-08-17T13:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/tagomics-launches-liquipath-a-first-in-class-cfdna-blood-test-for-multi-organ-drug-safety-monitoring 2026-08-17T12:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tagomics-launches-liquipath-a-first-in-class-cfdna-blood-test-for-multi-organ-drug-safety-monitoring 2026-08-17T12:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/dongguk-university-researchers-develop-electromagnetically-controllable-gene-switch-for-remote-gene-therapy 2026-08-17T11:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dongguk-university-researchers-develop-electromagnetically-controllable-gene-switch-for-remote-gene-therapy 2026-08-17T11:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/broccoli-compound-sulforaphane-shows-preclinical-promise-for-friedreich-ataxia 2026-08-17T10:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/broccoli-compound-sulforaphane-shows-preclinical-promise-for-friedreich-ataxia 2026-08-17T10:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/tadalafil-an-erectile-dysfunction-drug-draws-growing-interest-as-a-potential-longevity-and-cardiovascular-therapy 2026-08-17T09:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tadalafil-an-erectile-dysfunction-drug-draws-growing-interest-as-a-potential-longevity-and-cardiovascular-therapy 2026-08-17T09:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/uae-becomes-first-country-to-approve-rinvoq-upadacitinib-for-non-segmental-vitiligo 2026-08-17T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-becomes-first-country-to-approve-rinvoq-upadacitinib-for-non-segmental-vitiligo 2026-08-17T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/nice-expands-access-to-allergy-immunotherapy-tablets-for-children-as-young-as-five 2026-08-17T09:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-expands-access-to-allergy-immunotherapy-tablets-for-children-as-young-as-five 2026-08-17T09:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/chester-medical-acquires-power-health-products-to-build-end-to-end-nutraceutical-offering 2026-08-17T09:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chester-medical-acquires-power-health-products-to-build-end-to-end-nutraceutical-offering 2026-08-17T09:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/dayone-launches-singapore-s-first-biological-data-center-prototype-with-cortical-labs-and-nus-medicine 2026-08-17T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dayone-launches-singapore-s-first-biological-data-center-prototype-with-cortical-labs-and-nus-medicine 2026-08-17T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/tcs-launches-agenthub-to-scale-agentic-ai-across-drug-development-and-pharmacovigilance 2026-08-17T07:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcs-launches-agenthub-to-scale-agentic-ai-across-drug-development-and-pharmacovigilance 2026-08-17T07:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/antarctic-fungi-offer-new-hope-for-alzheimer-s-drug-discovery 2026-08-17T07:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antarctic-fungi-offer-new-hope-for-alzheimer-s-drug-discovery 2026-08-17T07:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-drug-monitoring-emerges-as-key-strategy-to-optimize-biologic-therapy-in-pediatric-ibd 2026-08-17T06:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-drug-monitoring-emerges-as-key-strategy-to-optimize-biologic-therapy-in-pediatric-ibd 2026-08-17T06:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-wins-us-lipitor-antitrust-appeal-closing-decade-long-case 2026-08-17T05:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-wins-us-lipitor-antitrust-appeal-closing-decade-long-case 2026-08-17T05:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-revised-drugs-medical-devices-and-cosmetics-bill-2026-restructures-national-drug-regulatory-system 2026-08-17T05:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-revised-drugs-medical-devices-and-cosmetics-bill-2026-restructures-national-drug-regulatory-system 2026-08-17T05:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/sprint-interval-exercise-triggers-a-distinct-molecular-surge-linked-to-cardiometabolic-health 2026-08-17T03:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sprint-interval-exercise-triggers-a-distinct-molecular-surge-linked-to-cardiometabolic-health 2026-08-17T03:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/cognizant-and-benchling-partner-to-accelerate-kyowa-kirin-s-r-d-with-ai-platform 2026-08-17T02:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognizant-and-benchling-partner-to-accelerate-kyowa-kirin-s-r-d-with-ai-platform 2026-08-17T02:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/prices-of-52-life-saving-drugs-in-pakistan-expected-to-be-fixed-this-month 2026-08-17T01:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prices-of-52-life-saving-drugs-in-pakistan-expected-to-be-fixed-this-month 2026-08-17T01:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/antimalarial-compound-cabamiquine-hailed-as-exciting-step-forward-in-fight-against-malaria 2026-08-16T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antimalarial-compound-cabamiquine-hailed-as-exciting-step-forward-in-fight-against-malaria 2026-08-16T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/olema-oncology-appoints-jason-o-byrne-as-cfo-ahead-of-pivotal-opera-01-data 2026-08-16T22:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-oncology-appoints-jason-o-byrne-as-cfo-ahead-of-pivotal-opera-01-data 2026-08-16T22:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/belly-fat-outperforms-bmi-in-predicting-heart-disease-risk-major-study-finds 2026-08-16T22:53:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belly-fat-outperforms-bmi-in-predicting-heart-disease-risk-major-study-finds 2026-08-16T22:53:04+00:00 hourly 0.9 https://trial.medpath.com/news/cyclospora-outbreak-and-salmonella-recalls-drive-renewed-focus-on-food-safety-and-local-produce 2026-08-16T22:52:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclospora-outbreak-and-salmonella-recalls-drive-renewed-focus-on-food-safety-and-local-produce 2026-08-16T22:52:51+00:00 hourly 0.9 https://trial.medpath.com/news/seth-klarman-s-baupost-group-fully-exits-vaxcyte-ahead-of-pivotal-vax-31-phase-3-readout 2026-08-16T21:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seth-klarman-s-baupost-group-fully-exits-vaxcyte-ahead-of-pivotal-vax-31-phase-3-readout 2026-08-16T21:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/j-k-high-court-refuses-to-quash-criminal-proceedings-against-pharma-directors-in-not-of-standard-quality-drug-case 2026-08-16T21:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-k-high-court-refuses-to-quash-criminal-proceedings-against-pharma-directors-in-not-of-standard-quality-drug-case 2026-08-16T21:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-plays-a-critical-role-in-weight-maintenance-and-cardiometabolic-health-independent-of-weight-loss-drugs 2026-08-16T17:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exercise-plays-a-critical-role-in-weight-maintenance-and-cardiometabolic-health-independent-of-weight-loss-drugs 2026-08-16T17:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-q1fy27-net-profit-slumps-57-as-lenalidomide-revenue-declines 2026-08-16T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-q1fy27-net-profit-slumps-57-as-lenalidomide-revenue-declines 2026-08-16T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/iowa-s-rising-cancer-rates-emerge-as-defining-issue-in-midterm-elections 2026-08-16T16:58:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iowa-s-rising-cancer-rates-emerge-as-defining-issue-in-midterm-elections 2026-08-16T16:58:36+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-unveils-national-strategy-to-build-biopharmaceutical-ecosystem-for-biosimilars-and-vaccines 2026-08-16T16:58:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-unveils-national-strategy-to-build-biopharmaceutical-ecosystem-for-biosimilars-and-vaccines 2026-08-16T16:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-skin-cancer-patient-still-standing-14-years-after-immunotherapy-trial 2026-08-16T16:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-skin-cancer-patient-still-standing-14-years-after-immunotherapy-trial 2026-08-16T16:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-named-a-winner-of-the-2026-metro-atlanta-top-workplaces-award-amid-2-billion-biomanufacturing-expansion 2026-08-16T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-named-a-winner-of-the-2026-metro-atlanta-top-workplaces-award-amid-2-billion-biomanufacturing-expansion 2026-08-16T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/scalp-cooling-capacity-doubles-at-two-south-east-hospitals-to-reduce-chemotherapy-related-hair-loss 2026-08-16T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scalp-cooling-capacity-doubles-at-two-south-east-hospitals-to-reduce-chemotherapy-related-hair-loss 2026-08-16T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/india-urged-to-leverage-health-data-and-ai-to-pole-vault-toward-affordable-healthcare 2026-08-16T14:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-urged-to-leverage-health-data-and-ai-to-pole-vault-toward-affordable-healthcare 2026-08-16T14:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/turkiye-moves-to-localize-production-of-cancer-sma-and-immunotherapy-medicines 2026-08-16T14:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turkiye-moves-to-localize-production-of-cancer-sma-and-immunotherapy-medicines 2026-08-16T14:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-plant-seeds-produce-bovine-b-casein-paving-the-way-for-cow-free-dairy-proteins 2026-08-16T12:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-plant-seeds-produce-bovine-b-casein-paving-the-way-for-cow-free-dairy-proteins 2026-08-16T12:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/cansinobio-s-adolescent-and-adult-pertussis-vaccine-nda-accepted-by-china-s-nmpa 2026-08-16T12:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansinobio-s-adolescent-and-adult-pertussis-vaccine-nda-accepted-by-china-s-nmpa 2026-08-16T12:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-neurosurgeon-cracks-decades-old-crouzeix-s-conjecture-using-chatgpt 2026-08-16T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-neurosurgeon-cracks-decades-old-crouzeix-s-conjecture-using-chatgpt 2026-08-16T11:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/how-mrna-vaccines-work-and-where-vaccine-science-is-heading-next 2026-08-16T11:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-mrna-vaccines-work-and-where-vaccine-science-is-heading-next 2026-08-16T11:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/ticks-carrying-lyme-disease-reach-northeast-level-infection-rates-in-western-north-carolina-residential-yards 2026-08-16T07:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ticks-carrying-lyme-disease-reach-northeast-level-infection-rates-in-western-north-carolina-residential-yards 2026-08-16T07:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/yangcheon-gu-launches-free-malaria-self-test-kits-to-catch-infections-early 2026-08-16T03:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yangcheon-gu-launches-free-malaria-self-test-kits-to-catch-infections-early 2026-08-16T03:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-dialysis-how-advances-in-kidney-care-are-giving-patients-a-second-chance 2026-08-16T02:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-dialysis-how-advances-in-kidney-care-are-giving-patients-a-second-chance 2026-08-16T02:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/anthony-fauci-s-public-health-legacy-a-career-spanning-aids-ebola-and-covid-19 2026-08-16T01:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthony-fauci-s-public-health-legacy-a-career-spanning-aids-ebola-and-covid-19 2026-08-16T01:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/zamfara-state-intensifies-crackdown-on-illegal-medicine-sales-and-hawking 2026-08-15T22:54:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zamfara-state-intensifies-crackdown-on-illegal-medicine-sales-and-hawking 2026-08-15T22:54:29+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-pursues-omani-partnership-to-expand-biotech-and-pharmaceutical-r-d 2026-08-15T22:54:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-pursues-omani-partnership-to-expand-biotech-and-pharmaceutical-r-d 2026-08-15T22:54:20+00:00 hourly 0.9 https://trial.medpath.com/news/youth-associated-protein-timp2-rejuvenates-brain-immune-cells-in-aged-mice 2026-08-15T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/youth-associated-protein-timp2-rejuvenates-brain-immune-cells-in-aged-mice 2026-08-15T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/problematic-drug-use-in-israel-surges-post-october-7-with-sedatives-and-opioids-showing-steepest-increases 2026-08-15T21:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/problematic-drug-use-in-israel-surges-post-october-7-with-sedatives-and-opioids-showing-steepest-increases 2026-08-15T21:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/newer-blood-thinners-noacs-may-slow-cognitive-decline-in-alzheimer-s-patients-with-atrial-fibrillation 2026-08-15T20:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newer-blood-thinners-noacs-may-slow-cognitive-decline-in-alzheimer-s-patients-with-atrial-fibrillation 2026-08-15T20:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-upadacitinib-shows-promise-for-restoring-skin-colour-in-non-segmental-vitiligo 2026-08-15T20:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-upadacitinib-shows-promise-for-restoring-skin-colour-in-non-segmental-vitiligo 2026-08-15T20:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/madrid-hospital-creates-first-bone-metamaterial-prosthesis-preventing-leg-amputation 2026-08-15T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madrid-hospital-creates-first-bone-metamaterial-prosthesis-preventing-leg-amputation 2026-08-15T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/rnai-therapeutics-expand-beyond-the-liver-as-sirna-drug-development-accelerates 2026-08-15T19:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rnai-therapeutics-expand-beyond-the-liver-as-sirna-drug-development-accelerates 2026-08-15T19:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-mini-guts-bring-personalised-ibd-treatment-for-children-a-step-closer 2026-08-15T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-grown-mini-guts-bring-personalised-ibd-treatment-for-children-a-step-closer 2026-08-15T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/kmtpa-and-yanolja-research-sign-mou-to-build-an-integrated-k-medical-wellness-tourism-ecosystem 2026-08-15T17:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kmtpa-and-yanolja-research-sign-mou-to-build-an-integrated-k-medical-wellness-tourism-ecosystem 2026-08-15T17:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/polyu-develops-ai-virtual-patient-simulation-system-for-precision-cancer-care 2026-08-15T17:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyu-develops-ai-virtual-patient-simulation-system-for-precision-cancer-care 2026-08-15T17:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/aizen-therapeutics-inks-multi-program-deal-to-advance-oral-biologics-with-dax-ai-platform 2026-08-15T16:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aizen-therapeutics-inks-multi-program-deal-to-advance-oral-biologics-with-dax-ai-platform 2026-08-15T16:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-s-nazeeh-johnson-suspended-six-games-after-positive-ped-test-tied-to-fertility-drug-clomid 2026-08-15T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-s-nazeeh-johnson-suspended-six-games-after-positive-ped-test-tied-to-fertility-drug-clomid 2026-08-15T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/hydrocolloid-patches-from-acne-treatment-to-blister-care-the-science-behind-a-beauty-staple 2026-08-15T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrocolloid-patches-from-acne-treatment-to-blister-care-the-science-behind-a-beauty-staple 2026-08-15T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/thbs1-macrophages-drive-an-immunosuppressive-tumor-microenvironment 2026-08-15T16:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thbs1-macrophages-drive-an-immunosuppressive-tumor-microenvironment 2026-08-15T16:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-plus-lenvatinib-improves-disease-control-in-previously-treated-advanced-renal-cell-carcinoma 2026-08-15T15:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belzutifan-plus-lenvatinib-improves-disease-control-in-previously-treated-advanced-renal-cell-carcinoma 2026-08-15T15:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/cct7-expression-emerges-as-a-prognostic-marker-in-lung-adenocarcinoma 2026-08-15T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cct7-expression-emerges-as-a-prognostic-marker-in-lung-adenocarcinoma 2026-08-15T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-confirms-human-h1n2v-swine-flu-case-in-fair-exhibitor 2026-08-15T14:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-confirms-human-h1n2v-swine-flu-case-in-fair-exhibitor 2026-08-15T14:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-advances-can-2409-toward-bla-submission-targeting-first-commercial-product-in-2027 2026-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-advances-can-2409-toward-bla-submission-targeting-first-commercial-product-in-2027 2026-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-q1-profit-slumps-57-on-lenalidomide-sales-erosion-plans-2000-crore-qip-for-acquisitions 2026-08-15T10:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-q1-profit-slumps-57-on-lenalidomide-sales-erosion-plans-2000-crore-qip-for-acquisitions 2026-08-15T10:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/stopping-myopia-treatment-safely-understanding-and-managing-the-rebound-effect 2026-08-15T07:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stopping-myopia-treatment-safely-understanding-and-managing-the-rebound-effect 2026-08-15T07:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-pharma-america-doses-first-patient-in-phase-1-2a-trial-of-ipsc-derived-cell-therapy-dsp-3077-for-retinitis-pigmentosa 2026-08-15T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sumitomo-pharma-america-doses-first-patient-in-phase-1-2a-trial-of-ipsc-derived-cell-therapy-dsp-3077-for-retinitis-pigmentosa 2026-08-15T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-profiling-of-high-risk-pediatric-tumors-reveals-actionable-alterations-in-nearly-one-quarter-of-patients 2026-08-15T03:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-profiling-of-high-risk-pediatric-tumors-reveals-actionable-alterations-in-nearly-one-quarter-of-patients 2026-08-15T03:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-wins-fda-accelerated-approval-for-zenbexus-its-first-celmod-therapy-for-multiple-myeloma 2026-08-15T01:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-wins-fda-accelerated-approval-for-zenbexus-its-first-celmod-therapy-for-multiple-myeloma 2026-08-15T01:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/automated-mri-pipeline-improves-evaluation-of-experimental-stroke-therapies-across-multicenter-preclinical-studies 2026-08-15T01:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-mri-pipeline-improves-evaluation-of-experimental-stroke-therapies-across-multicenter-preclinical-studies 2026-08-15T01:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/wolfe-research-upgrades-abbott-labs-and-abbvie-to-outperform-amid-in-line-inflation-data 2026-08-15T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wolfe-research-upgrades-abbott-labs-and-abbvie-to-outperform-amid-in-line-inflation-data 2026-08-15T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/appeals-court-sides-with-trump-in-fight-over-subpoena-of-gender-affirming-care-provider 2026-08-14T23:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appeals-court-sides-with-trump-in-fight-over-subpoena-of-gender-affirming-care-provider 2026-08-14T23:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trials-of-chemogenetic-dreadd-therapies-in-china-stun-us-neuroscientists 2026-08-14T23:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-trials-of-chemogenetic-dreadd-therapies-in-china-stun-us-neuroscientists 2026-08-14T23:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-research-horizons-charity-capital-model-targets-broken-childhood-cancer-market-after-1-5b-myricx-exit 2026-08-14T23:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-research-horizons-charity-capital-model-targets-broken-childhood-cancer-market-after-1-5b-myricx-exit 2026-08-14T23:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/speed-of-light-the-astro-foundation-awards-2-4-million-to-accelerate-radiation-medicine-research 2026-08-14T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/speed-of-light-the-astro-foundation-awards-2-4-million-to-accelerate-radiation-medicine-research 2026-08-14T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/prescription-drug-prices-fall-3-1-year-over-year-in-july-steepest-decline-in-over-60-years 2026-08-14T23:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prescription-drug-prices-fall-3-1-year-over-year-in-july-steepest-decline-in-over-60-years 2026-08-14T23:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/leonabio-on-track-to-complete-phase-3-elaine-3-enrollment-for-lasofoxifene-in-esr1-mutated-metastatic-breast-cancer-in-4q-2026 2026-08-14T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leonabio-on-track-to-complete-phase-3-elaine-3-enrollment-for-lasofoxifene-in-esr1-mutated-metastatic-breast-cancer-in-4q-2026 2026-08-14T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/news/summer-covid-19-surge-rises-again-across-the-us-though-milder-than-prior-waves 2026-08-14T21:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summer-covid-19-surge-rises-again-across-the-us-though-milder-than-prior-waves 2026-08-14T21:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-properties-acquires-former-pfizer-seagen-biomanufacturing-facility-in-everett-for-78-million 2026-08-14T20:56:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-properties-acquires-former-pfizer-seagen-biomanufacturing-facility-in-everett-for-78-million 2026-08-14T20:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/abdominal-obesity-combined-with-vitamin-d-deficiency-more-than-doubles-death-risk-after-age-50 2026-08-14T20:56:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abdominal-obesity-combined-with-vitamin-d-deficiency-more-than-doubles-death-risk-after-age-50 2026-08-14T20:56:28+00:00 hourly 0.9 https://trial.medpath.com/news/vivosim-labs-ai-powered-3d-tissue-models-report-91-liver-toxicity-accuracy-amid-fda-nam-momentum 2026-08-14T20:56:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivosim-labs-ai-powered-3d-tissue-models-report-91-liver-toxicity-accuracy-amid-fda-nam-momentum 2026-08-14T20:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/placental-biology-breakthrough-could-make-biologic-medicines-safer-during-pregnancy 2026-08-14T20:55:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/placental-biology-breakthrough-could-make-biologic-medicines-safer-during-pregnancy 2026-08-14T20:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/federal-ban-on-intoxicating-hemp-products-reshapes-risk-and-coverage-for-cannabis-industry 2026-08-14T20:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-ban-on-intoxicating-hemp-products-reshapes-risk-and-coverage-for-cannabis-industry 2026-08-14T20:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/new-miniature-microscope-watches-and-controls-individual-brain-cells-during-natural-movement 2026-08-14T20:53:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-miniature-microscope-watches-and-controls-individual-brain-cells-during-natural-movement 2026-08-14T20:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lantheus-tauklarify-pet-imaging-agent-for-alzheimer-s-assessment 2026-08-14T20:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lantheus-tauklarify-pet-imaging-agent-for-alzheimer-s-assessment 2026-08-14T20:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/most-americans-still-believe-outdated-antibiotic-guidance-study-finds 2026-08-14T20:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/most-americans-still-believe-outdated-antibiotic-guidance-study-finds 2026-08-14T20:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/quitting-alcohol-changes-the-brain-and-may-prime-it-for-relapse-mouse-study-finds 2026-08-14T20:53:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quitting-alcohol-changes-the-brain-and-may-prime-it-for-relapse-mouse-study-finds 2026-08-14T20:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/ema-revokes-avacopan-tavneos-after-gcp-breaches-in-advocate-trial-as-fda-hearing-looms 2026-08-14T20:53:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-revokes-avacopan-tavneos-after-gcp-breaches-in-advocate-trial-as-fda-hearing-looms 2026-08-14T20:53:36+00:00 hourly 0.9 https://trial.medpath.com/news/nanochon-receives-panama-regulatory-approval-to-initiate-first-in-human-study-of-chondrografttm-for-knee-cartilage-defects 2026-08-14T20:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanochon-receives-panama-regulatory-approval-to-initiate-first-in-human-study-of-chondrografttm-for-knee-cartilage-defects 2026-08-14T20:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/transcell-biologics-and-space-cargo-unlimited-partner-to-test-drugs-and-vaccines-on-human-mps-models-in-orbital-microgravity 2026-08-14T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcell-biologics-and-space-cargo-unlimited-partner-to-test-drugs-and-vaccines-on-human-mps-models-in-orbital-microgravity 2026-08-14T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/massachusetts-retailers-sue-to-block-emergency-kratom-ban-as-schedule-i-order-nears-effective-date 2026-08-14T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massachusetts-retailers-sue-to-block-emergency-kratom-ban-as-schedule-i-order-nears-effective-date 2026-08-14T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/aging-as-a-program-not-a-breakdown-new-theories-reframe-the-biology-of-growing-old 2026-08-14T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aging-as-a-program-not-a-breakdown-new-theories-reframe-the-biology-of-growing-old 2026-08-14T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-to-acquire-redx-pharma-in-125m-financing-backed-deal-forming-fibrosis-focused-fibrx-therapeutics 2026-08-14T16:50:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skye-bioscience-to-acquire-redx-pharma-in-125m-financing-backed-deal-forming-fibrosis-focused-fibrx-therapeutics 2026-08-14T16:50:40+00:00 hourly 0.9 https://trial.medpath.com/news/pexa-signs-7-5-msek-contract-with-top-10-global-pharma-for-ipf-clinical-study-using-pexa-2-1-systems 2026-08-14T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pexa-signs-7-5-msek-contract-with-top-10-global-pharma-for-ipf-clinical-study-using-pexa-2-1-systems 2026-08-14T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-secures-7-0-million-investment-from-perceptive-advisors-and-regains-nasdaq-compliance 2026-08-14T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-secures-7-0-million-investment-from-perceptive-advisors-and-regains-nasdaq-compliance 2026-08-14T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/valisure-sues-u-s-pharmacopeia-over-claims-its-drug-testing-methods-are-unvalidated 2026-08-14T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valisure-sues-u-s-pharmacopeia-over-claims-its-drug-testing-methods-are-unvalidated 2026-08-14T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/stair-climbing-tied-to-39-lower-cardiovascular-death-risk-in-meta-analysis-of-nearly-500000-adults 2026-08-14T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stair-climbing-tied-to-39-lower-cardiovascular-death-risk-in-meta-analysis-of-nearly-500000-adults 2026-08-14T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-completes-enrollment-in-phase-2-pynnacle-trial-plans-rezatapopt-nda-for-platinum-resistant-ovarian-cancer-in-q1-2027 2026-08-14T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharma-completes-enrollment-in-phase-2-pynnacle-trial-plans-rezatapopt-nda-for-platinum-resistant-ovarian-cancer-in-q1-2027 2026-08-14T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/cell-invisibility-cloak-could-enable-side-effect-free-diabetes-cell-therapy 2026-08-14T15:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-invisibility-cloak-could-enable-side-effect-free-diabetes-cell-therapy 2026-08-14T15:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-launches-industry-s-first-multi-agent-virtual-aging-cell-platform-centered-on-biological-age 2026-08-14T14:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-launches-industry-s-first-multi-agent-virtual-aging-cell-platform-centered-on-biological-age 2026-08-14T14:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-submits-cta-to-south-africa-for-phase-1b-trial-of-rsv-preventive-antibody-rsm01 2026-08-14T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-submits-cta-to-south-africa-for-phase-1b-trial-of-rsv-preventive-antibody-rsm01 2026-08-14T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/elevated-plasma-amyloid-b-1-40-linked-to-higher-postoperative-delirium-risk-after-cardiac-surgery 2026-08-14T14:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevated-plasma-amyloid-b-1-40-linked-to-higher-postoperative-delirium-risk-after-cardiac-surgery 2026-08-14T14:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/accountability-gaps-across-clinical-trial-contracts-undermine-study-execution 2026-08-14T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accountability-gaps-across-clinical-trial-contracts-undermine-study-execution 2026-08-14T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tauklarify-florquinitau-f-18-pet-tracer-for-detecting-tau-pathology-in-alzheimer-s-disease 2026-08-14T13:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tauklarify-florquinitau-f-18-pet-tracer-for-detecting-tau-pathology-in-alzheimer-s-disease 2026-08-14T13:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-shifts-to-a-summer-phenomenon-as-cases-rise-across-the-us 2026-08-14T13:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-shifts-to-a-summer-phenomenon-as-cases-rise-across-the-us 2026-08-14T13:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-of-epicor-yeast-postbiotic-triggers-rapid-selective-anti-inflammatory-cytokine-changes-in-healthy-adults 2026-08-14T13:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-of-epicor-yeast-postbiotic-triggers-rapid-selective-anti-inflammatory-cytokine-changes-in-healthy-adults 2026-08-14T13:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/finnish-study-links-habitual-coffee-consumption-to-leaner-body-composition-and-distinct-sex-hormone-signature 2026-08-14T12:54:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finnish-study-links-habitual-coffee-consumption-to-leaner-body-composition-and-distinct-sex-hormone-signature 2026-08-14T12:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/hdac-inhibition-turns-cancer-cell-quiescence-into-a-druggable-vulnerability-against-chemotherapy-resistant-ovarian-cancer 2026-08-14T11:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdac-inhibition-turns-cancer-cell-quiescence-into-a-druggable-vulnerability-against-chemotherapy-resistant-ovarian-cancer 2026-08-14T11:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-s-rsv-antiviral-ziresovir-receives-fda-approval-for-phase-ii-trial-in-critically-ill-infants 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-s-rsv-antiviral-ziresovir-receives-fda-approval-for-phase-ii-trial-in-critically-ill-infants 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-management-for-stroke-patients-beyond-the-jsh-2025-guidelines 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-pressure-management-for-stroke-patients-beyond-the-jsh-2025-guidelines 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/snapchat-launches-multi-cta-ad-format-to-help-pharma-brands-run-compliant-in-feed-rx-promotions 2026-08-14T09:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snapchat-launches-multi-cta-ad-format-to-help-pharma-brands-run-compliant-in-feed-rx-promotions 2026-08-14T09:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-trial-offers-first-hope-for-children-with-vanishing-white-matter-disease 2026-08-14T08:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-trial-offers-first-hope-for-children-with-vanishing-white-matter-disease 2026-08-14T08:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/ancient-living-fossils-reveal-first-visual-evidence-of-how-complex-life-may-have-begun 2026-08-14T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ancient-living-fossils-reveal-first-visual-evidence-of-how-complex-life-may-have-begun 2026-08-14T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/pcf-and-bayer-launch-first-annual-va-medical-education-program-for-prostate-cancer-care 2026-08-14T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcf-and-bayer-launch-first-annual-va-medical-education-program-for-prostate-cancer-care 2026-08-14T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/rilvegostomig-shows-durable-responses-in-checkpoint-inhibitor-resistant-nsclc-artemide-01-phase-i-ii-results 2026-08-14T03:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rilvegostomig-shows-durable-responses-in-checkpoint-inhibitor-resistant-nsclc-artemide-01-phase-i-ii-results 2026-08-14T03:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-launches-national-biobank-of-normal-tissues-from-deceased-donors-to-advance-precision-medicine 2026-08-14T03:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-launches-national-biobank-of-normal-tissues-from-deceased-donors-to-advance-precision-medicine 2026-08-14T03:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-reports-45-revenue-growth-as-zelsuvmi-molluscum-launch-surpasses-30000-units-dispensed 2026-08-14T03:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelthos-reports-45-revenue-growth-as-zelsuvmi-molluscum-launch-surpasses-30000-units-dispensed 2026-08-14T03:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/immunocine-launches-tumor-preservation-program-and-expands-personalized-dendritic-cell-therapy-access 2026-08-14T03:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocine-launches-tumor-preservation-program-and-expands-personalized-dendritic-cell-therapy-access 2026-08-14T03:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/managing-side-effects-of-modern-hiv-treatment-practical-strategies-and-emerging-long-acting-options 2026-08-14T01:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/managing-side-effects-of-modern-hiv-treatment-practical-strategies-and-emerging-long-acting-options 2026-08-14T01:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/aivita-biomedical-named-2026-prix-galien-usa-nominee-for-personalized-immunotherapy-platform 2026-08-14T00:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aivita-biomedical-named-2026-prix-galien-usa-nominee-for-personalized-immunotherapy-platform 2026-08-14T00:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/maze-therapeutics-appoints-paula-johnson-and-sophie-kornowski-to-board-of-directors 2026-08-14T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maze-therapeutics-appoints-paula-johnson-and-sophie-kornowski-to-board-of-directors 2026-08-14T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/journey-medical-reports-23-revenue-growth-in-q2-2026-driven-by-emrosi-momentum-in-rosacea 2026-08-13T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/journey-medical-reports-23-revenue-growth-in-q2-2026-driven-by-emrosi-momentum-in-rosacea 2026-08-13T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/liver-s-internal-clock-governs-timed-release-of-metabolism-regulating-proteins-pointing-to-chronotherapy-for-metabolic-disease 2026-08-13T23:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-s-internal-clock-governs-timed-release-of-metabolism-regulating-proteins-pointing-to-chronotherapy-for-metabolic-disease 2026-08-13T23:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/patient-founded-fund-helps-medical-student-showcase-research-on-mental-health-burden-in-als 2026-08-13T22:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-founded-fund-helps-medical-student-showcase-research-on-mental-health-burden-in-als 2026-08-13T22:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/antipsychotic-adrs-affect-61-7-of-ugandan-psychiatric-outpatients-study-finds 2026-08-13T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antipsychotic-adrs-affect-61-7-of-ugandan-psychiatric-outpatients-study-finds 2026-08-13T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-advances-ozekibart-toward-fda-decision-as-pfs-data-in-hnscc-looms 2026-08-13T21:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-advances-ozekibart-toward-fda-decision-as-pfs-data-in-hnscc-looms 2026-08-13T21:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-to-bring-nci-designated-comprehensive-cancer-care-to-lynchburg-this-fall 2026-08-13T20:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-to-bring-nci-designated-comprehensive-cancer-care-to-lynchburg-this-fall 2026-08-13T20:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/mosquito-bites-turned-into-immunity-boosters-wehi-and-msd-s-late-liver-stage-malaria-vaccination-approach 2026-08-13T20:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosquito-bites-turned-into-immunity-boosters-wehi-and-msd-s-late-liver-stage-malaria-vaccination-approach 2026-08-13T20:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/vinod-khosla-ai-is-creating-a-hyperabundance-of-new-drugs-but-testing-remains-18th-century 2026-08-13T20:47:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vinod-khosla-ai-is-creating-a-hyperabundance-of-new-drugs-but-testing-remains-18th-century 2026-08-13T20:47:50+00:00 hourly 0.9 https://trial.medpath.com/news/fewer-eclipse-related-eye-injuries-reported-after-uk-solar-eclipse-surgeon-says 2026-08-13T20:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fewer-eclipse-related-eye-injuries-reported-after-uk-solar-eclipse-surgeon-says 2026-08-13T20:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/bit-bio-launches-ioscreen-crispr-screening-platform-and-appoints-first-chief-technology-officer 2026-08-13T19:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bit-bio-launches-ioscreen-crispr-screening-platform-and-appoints-first-chief-technology-officer 2026-08-13T19:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/nova-scotia-invests-1-2-million-to-expand-verschuren-centre-s-precision-fermentation-biomanufacturing-capacity 2026-08-13T18:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nova-scotia-invests-1-2-million-to-expand-verschuren-centre-s-precision-fermentation-biomanufacturing-capacity 2026-08-13T18:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/nci-funded-study-targets-p-gp-to-reduce-mmae-induced-neuropathy-in-cancer-patients 2026-08-13T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nci-funded-study-targets-p-gp-to-reduce-mmae-induced-neuropathy-in-cancer-patients 2026-08-13T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/viral-rna-strategy-triples-mrna-lifespan-offering-path-to-longer-lasting-therapeutics 2026-08-13T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viral-rna-strategy-triples-mrna-lifespan-offering-path-to-longer-lasting-therapeutics 2026-08-13T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/poison-center-calls-for-xenobiotic-liver-injuries-surge-nearly-400-over-24-years 2026-08-13T17:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poison-center-calls-for-xenobiotic-liver-injuries-surge-nearly-400-over-24-years 2026-08-13T17:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/khartis-therapeutics-emerges-from-stealth-with-95-million-to-advance-first-oral-selective-igf-1r-inhibitor-for-thyroid-eye-disease 2026-08-13T16:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khartis-therapeutics-emerges-from-stealth-with-95-million-to-advance-first-oral-selective-igf-1r-inhibitor-for-thyroid-eye-disease 2026-08-13T16:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/union-county-spotlights-ohio-drug-recovery-court-with-over-50-success-rate 2026-08-13T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/union-county-spotlights-ohio-drug-recovery-court-with-over-50-success-rate 2026-08-13T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-for-second-lead-compound-in-cardiovascular-rna-collaboration 2026-08-13T16:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-for-second-lead-compound-in-cardiovascular-rna-collaboration 2026-08-13T16:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-case-report-details-16-7-month-pfs-in-platinum-relapsed-sclc-after-systemic-olvi-vec-plus-platinum-rechallenge 2026-08-13T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genelux-case-report-details-16-7-month-pfs-in-platinum-relapsed-sclc-after-systemic-olvi-vec-plus-platinum-rechallenge 2026-08-13T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-epigenetic-immune-regulatory-networks-emerge-as-therapeutic-targets-in-inflammation-and-disease 2026-08-13T15:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-epigenetic-immune-regulatory-networks-emerge-as-therapeutic-targets-in-inflammation-and-disease 2026-08-13T15:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-protein-opa1-deficiency-drives-sex-specific-fat-intake-and-obesity-study-finds 2026-08-13T15:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondrial-protein-opa1-deficiency-drives-sex-specific-fat-intake-and-obesity-study-finds 2026-08-13T15:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/hippocratic-ai-launches-agentic-orchestrators-to-coordinate-voice-ai-teams-for-healthcare-outcomes 2026-08-13T15:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hippocratic-ai-launches-agentic-orchestrators-to-coordinate-voice-ai-teams-for-healthcare-outcomes 2026-08-13T15:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/sirolimus-from-transplant-immunosuppressant-to-precision-therapeutic-across-rare-diseases-oncology-and-aging 2026-08-13T14:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirolimus-from-transplant-immunosuppressant-to-precision-therapeutic-across-rare-diseases-oncology-and-aging 2026-08-13T14:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/xanadu-and-university-of-alberta-partner-to-apply-quantum-computing-to-photodynamic-cancer-drug-discovery 2026-08-13T14:47:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xanadu-and-university-of-alberta-partner-to-apply-quantum-computing-to-photodynamic-cancer-drug-discovery 2026-08-13T14:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/fentanyl-deaths-drop-22-as-administration-expands-prevention-and-enforcement-efforts 2026-08-13T14:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fentanyl-deaths-drop-22-as-administration-expands-prevention-and-enforcement-efforts 2026-08-13T14:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-expands-alto-207-phase-3-program-in-treatment-resistant-depression-backed-by-100-million-financing 2026-08-13T13:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alto-neuroscience-expands-alto-207-phase-3-program-in-treatment-resistant-depression-backed-by-100-million-financing 2026-08-13T13:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/clover-health-delivers-first-full-year-profitability-trajectory-as-ai-powered-care-model-drives-48-membership-growth 2026-08-13T13:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-health-delivers-first-full-year-profitability-trajectory-as-ai-powered-care-model-drives-48-membership-growth 2026-08-13T13:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/canadians-cite-protecting-others-as-key-vaccine-motivator-yet-nearly-half-skipped-respiratory-vaccines-ahead-of-2026-2027-season 2026-08-13T12:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadians-cite-protecting-others-as-key-vaccine-motivator-yet-nearly-half-skipped-respiratory-vaccines-ahead-of-2026-2027-season 2026-08-13T12:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-fda-launches-nadr-program-to-accelerate-rare-disease-drug-development 2026-08-13T12:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-fda-launches-nadr-program-to-accelerate-rare-disease-drug-development 2026-08-13T12:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-reports-82-quelimmune-revenue-growth-as-neutralize-aki-trial-advances-toward-adult-aki-indication 2026-08-13T12:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seastar-medical-reports-82-quelimmune-revenue-growth-as-neutralize-aki-trial-advances-toward-adult-aki-indication 2026-08-13T12:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/aig-hospitals-and-johnson-johnson-partner-to-deploy-polyphonic-surgery-digital-ecosystem 2026-08-13T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aig-hospitals-and-johnson-johnson-partner-to-deploy-polyphonic-surgery-digital-ecosystem 2026-08-13T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/drugmakers-curb-swiss-reimbursement-applications-over-us-most-favoured-nation-pricing-policy 2026-08-13T11:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drugmakers-curb-swiss-reimbursement-applications-over-us-most-favoured-nation-pricing-policy 2026-08-13T11:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/orbusneich-reports-18-1-revenue-growth-and-advances-coronary-paclitaxel-dcb-trial-in-japan 2026-08-13T11:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbusneich-reports-18-1-revenue-growth-and-advances-coronary-paclitaxel-dcb-trial-in-japan 2026-08-13T11:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-agrees-amt-130-data-can-support-accelerated-approval-in-huntington-s-disease-driving-uniqure-re-rating 2026-08-13T10:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-agrees-amt-130-data-can-support-accelerated-approval-in-huntington-s-disease-driving-uniqure-re-rating 2026-08-13T10:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-bmj-review-identifies-most-effective-bipolar-disorder-treatments-across-age-groups-and-mood-phases 2026-08-13T10:47:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-bmj-review-identifies-most-effective-bipolar-disorder-treatments-across-age-groups-and-mood-phases 2026-08-13T10:47:30+00:00 hourly 0.9 https://trial.medpath.com/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-in-phase-3-rezilient3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-08-13T07:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-in-phase-3-rezilient3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-08-13T07:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/marcus-foundation-awards-28-7-million-to-advance-stem-cell-based-therapy-for-heart-attack-regeneration 2026-08-13T07:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marcus-foundation-awards-28-7-million-to-advance-stem-cell-based-therapy-for-heart-attack-regeneration 2026-08-13T07:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-leucovorin-prescriptions-rose-sevenfold-in-2025-after-federal-officials-touted-it-for-autism 2026-08-13T07:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-leucovorin-prescriptions-rose-sevenfold-in-2025-after-federal-officials-touted-it-for-autism 2026-08-13T07:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/penitrium-targets-tumor-pseudo-resistance-as-first-prostate-cancer-patient-dosed-and-fda-clears-us-phase-2a 2026-08-13T04:47:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penitrium-targets-tumor-pseudo-resistance-as-first-prostate-cancer-patient-dosed-and-fda-clears-us-phase-2a 2026-08-13T04:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-s-nafamostat-gains-kdigo-endorsement-as-nephro-crrt-trial-nears-completion 2026-08-13T03:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-s-nafamostat-gains-kdigo-endorsement-as-nephro-crrt-trial-nears-completion 2026-08-13T03:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/six-australian-biomed-startups-share-a-13-5m-in-cureator-funding-round 2026-08-13T03:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-australian-biomed-startups-share-a-13-5m-in-cureator-funding-round 2026-08-13T03:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-advances-three-phase-2-programs-as-boron-chemistry-pipeline-expands 2026-08-13T01:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-advances-three-phase-2-programs-as-boron-chemistry-pipeline-expands 2026-08-13T01:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/jury-selection-begins-in-meta-s-federal-trial-over-youth-mental-health-harms 2026-08-13T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jury-selection-begins-in-meta-s-federal-trial-over-youth-mental-health-harms 2026-08-13T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/missouri-childhood-vaccine-rates-fall-below-herd-immunity-threshold-as-executive-order-seeks-to-cut-recommended-vaccines 2026-08-12T23:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/missouri-childhood-vaccine-rates-fall-below-herd-immunity-threshold-as-executive-order-seeks-to-cut-recommended-vaccines 2026-08-12T23:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-from-undruggable-to-druggable-with-sotorasib-and-adagrasib 2026-08-12T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kras-g12c-from-undruggable-to-druggable-with-sotorasib-and-adagrasib 2026-08-12T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-clearance-and-mrd-may-identify-nsclc-patients-who-benefit-most-from-perioperative-nivolumab 2026-08-12T22:53:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-clearance-and-mrd-may-identify-nsclc-patients-who-benefit-most-from-perioperative-nivolumab 2026-08-12T22:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-galaxy-buds-gain-fda-clearance-for-over-the-counter-hearing-aid-feature 2026-08-12T22:52:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-galaxy-buds-gain-fda-clearance-for-over-the-counter-hearing-aid-feature 2026-08-12T22:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/dod-to-launch-three-year-pilot-covering-sperm-and-egg-freezing-for-deploying-service-members 2026-08-12T21:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-to-launch-three-year-pilot-covering-sperm-and-egg-freezing-for-deploying-service-members 2026-08-12T21:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-advances-firmonertinib-toward-pivotal-egfr-exon-20-nsclc-data-as-adc-pipeline-progresses 2026-08-12T20:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-advances-firmonertinib-toward-pivotal-egfr-exon-20-nsclc-data-as-adc-pipeline-progresses 2026-08-12T20:49:56+00:00 hourly 0.9